Dyslipidemia in systemic lupus erythematosus by LEONG KENG HONG
  






Leong Keng Hong 
MBBS , M,Med (Internal Medicine),MRCP (UK) 
FRCP (Edinburgh), FAMS (Rheumatology) 
 
 
A THESIS SUBMITTED FOR THE DOCTORATE OF MEDICINE 
DEPARTMENT OF MEDICINE 






The Candidate wishes  to thank 
 
Professor Chan  Heng Leong for his invaluable advice and input. 
 
A/Professor Fong Kok Yong for his insightful comments 
 
In addition he wishes to express his gratitude to collaborators at the Royal Hospital for 
Rheumatic Diseases, Bath and the Department of Rheumatology and Immunology at Tan 












Systemic Lupus Erythematosus (SLE)  is an illness with a poor prognosis in the past. In 
recent years, treatment options have improved and patients often survive more than ten 
years from the time of diagnosis. This has given rise to new problems related to organ 
damage and long term side effects of medications. One of these problems which only 
recently has been recognised is dyslipidemia.  
 
In a study of 100 Singaporean SLE patients with a mean age of 32, 35% had severe lipid 
abnormalities of high LDL, high TG, low HDL and abnormal TC/HDL ratios. The mean 
LDL was 233 mg/dl, HDL 51 mg/dl, total cholesterol 355 mg/dl, TG 354 mg/dl and ratio of 
7.8 These abnormalities were found to be associated with the presence of lupus nephritis 
and high current daily doses of prednisolone. Lupus nephritis was defined as in the 1982 
ARA criteria for SLE. 27 out of 35 with abnormal lipid profiles had nephritis compared to 
only 10 out of 27 with normal lipid profiles (p<0.001). The mean current dose of patients 
with normal lipid profiles was 9 mg and 23.5 mg for those with abnormal profiles 
(p<0.001). Lupus activity was assessed using Lupus Activity Criteria Count and although 
there was a trend towards lower HDL it did not reach significance after controlling for renal 
disease and other confounding factors. 
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 In a different SLE cohort in Bath, abnormalities seem to be related to lipoprotein lipase 
suppression and this could be associated with lupus activity. In this cohort there were far 
fewer patients with lupus nephritis and many were not on systemic corticosteroids. 
Compared to age and gender matched control subjects these patients had low HDL 2 
subfraction (17.5 mg/dl vs 21.8 mg/dl, p<0.023) and  low apoprotein A I levels (120 mmol/l 
vs 142 mmol/l, p<0.0001). Therefore,  hyperlipidemia in SLE is associated several different 
factors including the presence of nephrotic syndrome, active lupus and the use of systemic 
corticosteroids.  
 
Many studies have shown premature atherosclerosis to be a significant problem in 
rheumatic diseases including SLE. Although a five year follow up study of the Singapore 
cohort did not reveal new atherosclerotic events in these young patients, the risk of 
premature atherosclerosis is a real one the older they get. To prevent the premature onset of 
atherosclerotic complications such as stroke and myocardial infarction, hyperlipidemia in 
SLE patients should be diagnosed early and treated accordingly. 
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Systemic Lupus Erythematosus (SLE) is an illness with a poor prognosis in the past. In 
recent years, treatment options have improved and patients often survive more than ten 
years from the time of diagnosis. This has given rise to new problems related to organ 
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This thesis explores the relationship between dyslipidemia and systemic lupus 
erythematosus.  
 
Chapter Two entitled Lipids and Inflammation gives a background to the understanding of 
lipid metabolism, the relationship between lipid abnormalities and inflammation and the 
increasingly recognized importance of inflammation in the development of atherosclerosis. 
 
Chapter Three – Lipids and SLE discusses the importance of hyperlipidemia in SLE 
patients in terms of causing premature atherosclerosis. It also presents some of the possible 
contributing factors to development of lipid abnormalities in SLE patients. 
 
Chapter Four – Aims and Methods states the aims of the thesis and the methods used to test 
various hypotheses in the area of lipids and SLE. 
 
Chapter Five -  How Common is Hyperlididemia in SLE? presents data from two cohorts of 
SLE patients to show that the extent of hyperlipidemia varies in different patient subsets but 
are common in lupus cohorts with severe lupus, who have a high prevalence of renal 






Chapter Six – What are the Risk Factors for Hyperlipidemia in SLE? examines risk factors 
for hyperlipidemia in the SLE patients studied. Attention is paid in particular to 
corticosteroid use, presence of renal disease and active lupus. 
 
Chapter Seven – What could be the clinical consequences of hyperlipidemia in SLE? 
presents data from the more severe lupus cohort after a period of five years.  
 
Chapter Eight is a discussion on the whole thesis, including suggestions regarding the plan 
of management in SLE patients who have hyperlipidemia. 
 
































 I  a.   LIPID  METABOLISM 
Lipid Composition 
Lipoproteins are complex molecules which transport lipids through the plasma. Each 
lipoprotein molecule has a non-polar core of hydrophobic lipids such as triglycerides and 
cholesterol ester and a polar coat of phospholipids and free cholesterol, within which are 
various apoproteins. There are five main types of lipoprotein which differ in their 
composition of lipid and the type of  apolipoprotein. Apolipoprotein A (apoA) is the major 
apolipoprotein in high density lipoprotein (HDL) and apolipoprotein B (apo B) is the major 
structural apolipoprotein of the other lipoproteins, chylomicrons, very low density 
lipoprotein (VLDL), intermediate density lipoprotein (IDL) and low density lipoprotein  
(LDL). The full apoB (apo B100) is found in VLDL, IDL and LDL but a truncated form, 
apo B48 is found in chylomicrons made by gut cells. The main cholesterol-carrying 
lipoproteins are LDL and HDL and the main triglyceride-carrying lipoproteins are 
chylomicrons and VLDL. 
 
Major lipoproteins are heterogenous and the subclasses can be detected by precipitation or 
ultracentrifugation. HDL can be separated into HDL2 and HDL3 whereas LDL exists in 
three main subclasses, namely LDL1, LDL2, LDL3. LDL2 is the predominant subclass. 
VLDL can be separated into VLDL1, VLDL2, VLDL3. Changes in proportion of 
lipoprotein subclasses will not be apparent on basic lipid screening but may have an 
important bearing on risk of atherosclerosis. 
 10
 Exogenous pathway 
 
This pathway deals with the handling of dietary lipids. Chylomicrons carry triglycerides 
and cholesterol from the intestine to adipose tissue and skeletal muscle. Lipoprotein lipase 
then liberates free fatty acid and monoglycerides which cross the endothelium to peripheral 




Triglycerides are synthesised in the liver and incorporated into VLDL which is a substrate 
for lipoprotein lipase in peripheral tissue where triglycerides are hydrolysed. VLDL 
becomes IDL which is either taken back up by the liver or loses more triglyceride and 
apolipoproteins and becomes cholesterol rich LDL. Both the liver and extrahepatic tissues 
that utilise cholesterol recognise LDL by receptor mediated pathways. A variable amount 
of LDL is scavenged by the reticuloendothelial system. HDL can accept cholesterol from 
cholesterol replete tissues. A HDL core cholesterol ester is formed when cholesterol is 
esterified on the surface of HDL by lecithin:cholesterol acyltransferase. This ester can then 
be exchanged with VLDL or IDL through the action of cholesterol ester transfer protein or 










I b. LIPIDS AND INFLAMMATION  
 
Essential Fatty Acids 
 
Fatty acids are core components of complex lipids, they are incorporated into cell 
membranes and serve as precursors for prostaglandins and leucotrienes. Omega 3 and 
omega 6 fatty acids have been investigated as therapeutic agents for reducing inflammation 




Polyunsaturated fatty acids are the main target for lipoperoxidative injury by oxygen free 
radicals. They can be oxidised by endothelial cells and macrophages. Oxidised LDL may 
exert proinflammatory effects. LDL is modified by contact with endothelial cells and 
becomes more readily taken up by receptors on scavenger cells which become lipid-laden 
foam cells. This is an early event in atheroma formation. LDL3 is more likely to be 
oxidised, is more immunogenic and is more readily taken up by scavenger pathways. 





Cytokines and lipoprotein lipase activity 
 
Lipoprotein lipase is a membrane bound enzyme responsible for liberation of fatty acids 
from VLDL resulting in formation of LDL. Reduction in activity of this enzyme would 
result in reduced clearance of VLDL-triglyceride and an associated rise in plasma 
triglycerides. Normal or slightly low LDL-cholesterol would be expected. HDL would also 
tend to fall. 
 
Lipoprotein lipase is inhibited by several cytokines such as tumour necrosis factor alpha, 
interleukin 1 and gamma-interferon. These cytokines are upregulated in inflammation and 
have been shown to be increased in active SLE. Evidence of this relationship between 
cytokines and lipoprotein lipase exists in the demonstration that 24 hour infusion of human 









I c The role of  cytokines and  inflammation in atherosclerotic disease 
 
Increasingly it is recognized that inflammation plays an important factor in the 
pathogenesis of atherosclerosis. High sensitivity C reactive protein (hsCRP) has been 
shown to be a reliable prognostic predictor in stroke and ischemic heart disease. Yamashita 
et al (5) analysed various inflammatory markers such as interleukins IL-6, IL-10, IL12, 
IL-28 and hsCRP in 40 patients with unstable angina, 39 patients with stable angina and 52 
age and gender matched controls. HsCRP was significantly higher in the unstable angina 
patients, was positively correlated with the pro-inflammatory cytokines IL-6, IL-12 and 
IL-18 and negatively associated with the anti-inflammatory cytokine IL-10.  
 
C-reactive protein predicts progression of atherosclerosis measured at various sites in the 
arterial tree. Van Der Meer at al (6) measured CRP levels in 773 subjects in the Rotterdam 
Study. Subclinical atherosclerosis was assessed at various sites at two points of time, with a 
mean duration between measurements of 6.5 years. After adjustment for age, sex and 
smoking, odds ratios (OR) associated with CRP levels in the highest versus lowest quartiles 
were increased for progression of atherosclerosis at carotid, aortic, iliac and lower 
extremity sites. The OR for generalized progression of atherosclerosis as indicated by a 
composite score was 4.5 (95%CI 2.3-8.5). This is as high as OR’s for traditional 
cardiovascular risk factors such as high cholesterol, hypertension and smoking. 
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 The mechanisms by which inflammation and C-reactive protein contributes to 
atherosclerosis are not completely understood. Devaraj et al (7) showed recently that CRP 
induces plasminogen activator inhibitor-1 expression and activity in human aortic 
endothelial cells. More recent studies show that IL-18 plays a significant role in 
atherosclerosis. Elhage et al  (8) showed that there was reduced atherosclerosis in IL-18 
deficient apolipoprotein E-knockout mice. Mallat et al (9) found increased plasma 
concentrations of IL-18 in patients with acute coronary syndromes and this correlated with 
the severity of myocardial dysfunction. Yamaoka-Tojo et al (10) found that human 
recombinant C-reactive protein induced IL-18 in human endothetial cells providing a link 
between the two that may suggest a mechanism by which C-reactive protein is important to 
atherosclerotic events. Another interesting observation by Esposito et al (11) was that 
weight loss reduces circulating IL-18 levels in obese women.  
 
Treatment of hyperlipidemia with statins has effects on hsCRP. This was shown by van 
Wissen et al (12)  in a randomized double blind 2 year trial with 325 patients with familial 
hypercholesterolemia treated with atorvastatin 80 mg versus simvastatin 40 mg. The extent 
of hsCRP reduction was associated with improvement in progression of atherosclerosis as 
measured using intima media thickness of carotid artery segments. 
 
In SLE, many patients suffer from multiorgan involvement and have a high degree of 
inflammation with elevated acute phase reactants. This may have a bearing on the increased 
frequency of coronary artery disease and stroke observed in SLE patients. Esdaile et al (13) 
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assessed retrospectively two SLE cohorts in relation to traditional Framingham risk factors 
and the presence of vascular events such as nonfatal myocardial infarction (MI), death due 
to coronary heart disease (CHD), stroke and overall CHD (nonfatal MI, death due to CHD, 
angina pectoris and congestive heart failure due to CHD). He found that the traditional risk 
































2  a.  THE RELEVANCE OF LIPID ABNORMALITIES TO PATIENTS WITH                
SYSTEMIC LUPUS ERYTHEMATOSUS 
 
Systemic lupus erythematosus (SLE) is an autoimmune disease with protean manifestations 
affecting mainly young women (14). The age of onset is generally from 20 to 50 and female 
to male ratio is 9:1. It is a relatively new disease although reference was made to “lupus” 
since the early 20th century but it was not until 1982 before the international community 
agreed on classification criteria for SLE as put forth by the American Rheumatism 
Association (ARA) (15) which has now become the American College of Rheumatology. 
Up to the 1970’s, SLE had a poor prognosis and many medical textbooks in those days 
painted a bleak picture. Things have gradually improved and nowadays, the 10 year 
survival of most SLE populations is in the region of 80 or 90 percent. Many patients are 
able to lead fairly normal lives, holding on to full time jobs and bear children as well. Now 
that SLE patients can live longer, the impact of uncontrolled active lupus disease has 
lessened but then complications arising from chronic illness and prolonged therapy with 
potentially toxic drugs have increased. Many of the drugs used in lupus are 
immunosuppressive in nature and hence the SLE patient is more prone to getting infections 
some of which are serious and life-threatening. Corticosteroid therapy is unfortunately still 
the mainstay in the treatment of lupus. The onus is on the rheumatologist to use the lowest 
possible dose which will control the disease and yet have minimal side effects. This can be 
achieved with steroid sparing agents or second line agents. The best agent varies according 
to the clinical situation and include anti-malarial agents, cyclophosphamide, azathioprine, 
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methotrexate, intravenous immunoglobulin and newer drugs such as cyclosporin and 
mycophenolate mofetil. 
 
In spite of this, many patients do suffer from side effects of corticosteroid therapy. They 
include steroid induced osteoporosis, premature cataracts, hypertension, hyperlipidemia, 
diabetes mellitus and features of Cushing’s syndrome. In the light of this, treatment of SLE 
should not only be directed at treatment of active lupus disease but also would involve close 
monitoring for side effects due to medication or chronicity of illness. 
 
One of these side effects which has increasingly been recognised is hyperlipidemia and 
premature atherosclerosis. These problems would affect the long term outlook for these 
patients. Up to now, the research on SLE and hyperlipidemia has been fairly limited 
compared to that done regarding other side effects such as increased infections, avascular 
necrosis and steroid induced osteoporosis.  
 
SLE in Singapore is a relatively common rheumatological problem. Outcomes have been 
poor in the past due to various factors including poor patient compliance. Prognosis has 
steadily improved and patients nowadays survive long enough to develop problems such as 
hyperlipidemia.   
 
Abnormal lipid profiles have been described in SLE patients and premature atherosclerosis 
has been documented in lupus cohorts in the West. The risk of clinical thrombotic events 
increases in the presence of antiphospholipid syndrome and vasculitis.  
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 2b.  Contributing Factors to Abnormal Lipid Profiles in SLE 
 
In SLE, there are many risk factors for vascular events. These include the presence of 
anti-phospholipid antibodies, abnormal lipid profiles produced by illness, treatment or 
renal disease and less commonly concomitant vasculitis. Broadly speaking, the causes of 
dyslipidemia in SLE can be grouped into three main categories: use of corticosteroids, 
lupus activity and renal disease. 
 
Use of Corticosteroids 
 
The use of corticosteroids contributes to a Type IIb hyperlipidemia as does the presence of 
a nephrotic syndrome which is common in lupus nephritis. Ettinger et al (16) compared 46 
SLE patients and 30 controls and found that SLE patients who were on corticosteroids had 
higher levels of total cholesterol, total triglyceride and LDL-cholesterol. Those who were 




Lupus sera has been found to be atherogenic. Kabakov et al (17) showed that in the 
presence of lupus sera, lipid accumulation in cultured smooth muscle cells is increased 1.5 
to 6 fold compared with cells cultured with normal human sera from healthy donors. 
Incubation of the smooth muscle cells with circulating immune complexes isolated from 
lupus sera caused a 3 to 4 fold increase in intracellular cholesterol level. This atherogenic 
effect is generally due to LDL-containing immune complexes. 
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 Lipoprotein(a) also has great atherogenic potential. Takegoshi et al (18) reported a case of 
an 18-year-old SLE patient who had severe elevations of Lp(a) resulting in myocardial 
infarction and cerebral infarction. Rantapaan-Dahlqvist et al (19) showed that 93 patients 
with classical RA of moderately active disease had significantly increased levels of Lp(a). 
In those with concentrations above 480 mg/l there was a significant correlation between 
Lp(a) levels and acute phase reactants such as the platelet count and the erythrocyte 
sedimentation rate. Mechanisms for elevated Lp(a) are not clear. Although corticosteroids 
have been known to cause elevated levels of LDL-cholesterol, Aoki and Kawai (20) in fact 
showed that corticosteroids reduced the Lp(a) levels in a dose-dependent manner in patients 
who did not have nephrotic syndrome. The nephrotic syndrome rather than corticosteroid 
use contributes to high levels of Lp(a). 
 
The interplay between lipid abnormalities and the presence of antiphospholipid antibodies 
is likely to be complex. A plasma co-factor which is needed for thrombosis to occur in some 
patients harbouring anti-phospholipid antibodies has been identified as 
beta2-glycoprotein1 or apolipoprotein H. Whether lipoproteins other than beta2GP1 is 
involved in the pathogenesis of the anti-phospholipid syndrome is presently unknown. 
There would however be an additive risk of thrombotic clinical events if both the 
antiphospholipid syndrome and hyperlipidemia are present. This is shown by various 
studies. An increase in vascular disease in a set of SLE patients was found by MacGregor et 
al (21) in those with elevated triglyceride levels who also expressed anticardiolipin 
antibodies. In patients on prednisolone of more than 10 mg a day in the six months before 
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testing, there were increased levels of triglyceride and apoprotein B. Patients not on 
steroids did not have lipid abnormalities in this study. 
 
Lahita et al (22) showed that there is an association between the presence of anticardiolipin 
antibodies and lowered levels of serum cholesterol, HDL and apoA-I levels in SLE 
patients. In the 72 patients not on corticosteroids, serum total cholesterol was lower 
compared with 72 healthy blood donors. The SLE patients not on steroids were divided in 
those with and those without IgG anticardiolipin antibodies. Anticardiolipin positive 
patients had lower levels of total cholesterol, HDL-cholesterol and apo-AI compared to 
patient without anticardiolipin antibodies. 
 
Another potentially important mechanism is the effect of cytokines such as interleukin-1 
(IL-1) and tumour necrosis factor-alpha on lipoprotein lipase activity. The 
pro-inflammatory cytokines are upregulated in active SLE and suppress lipoprotein lipase 






 Renal Disease 
 
It is well known that lipid abnormalities exist in the nephrotic syndrome. Proteinuria is a 
known stimulus for increased lipid synthesis. Urinary loss of HDL may also be significant. 
Animal studies reveal that hyperlipidemia may accelerate deterioration of renal function 
and control of hyperlipidemia has been shown in these models to retard development of 
glomerulosclerosis and renal failure. 
 
In the nephrotic syndrome it is thought that there is overproduction of apolipoprotein B 
100. The stimulus for this overproduction is the loss of albumin and other macromolecules 
in the urine. Hepatic synthesis of cholesterol is increased and the increased hepatic 
cholesterol content results in a down regulation of synthesis of LDL receptors. This retards 
the clearance of LDL from the circulation and together with increased production of 
lipoproteins, LDL-cholesterol concentration can become grossly elevated. 
Hypertriglyceridemia can occur in the nephrotic syndrome from an overproduction of very 



























The candidate tries to explore in this thesis certain issues surrounding dyslipidemia and 
SLE: 
 
1) How common is hyperlipidemia in SLE in Singapore? 
2) What are the risk factors for  hyperlipidemia in SLE? 
3) What are the clinical consequences of hyperlipidemia in SLE? 
 
SLE is a heterogenous disease. For some time it is known than patient characteristics differ 
in different countries. For example, Oriental and Afro-Carribean patients are thought to 
have more severe lupus with higher prevalence of renal involvement than Caucasian 
patients (23, 24). 
 
The candidate wanted to establish the prevalence of hyperlipidemia in SLE patients in 
Singapore as there had been no data previously. Therefore a consecutive set of 100 SLE 
patients were studied at Tan Tock Seng Hospital which is one of the main referral centres 
for lupus in Singapore at the time of study. Findings from this study would give an idea of 




 To explore possible contributing factors to hyperlipidemia, the study of Singapore SLE 
patients can help to explore the role of corticosteroid use, presence of renal disease and the 
nephrotic syndrome and lupus activity. However it is difficult to separate the role of lupus 
activity from steroid use and renal disease. It would be preferable to study a set of lupus 
patients who may have active lupus from involvement other than renal, and who have a 
lesser usage of corticosteroids. A Western lupus cohort would fit these criteria. The author 
studied a group of SLE patients from Bath with the intention to study this possible 
relationship between lupus activity and lipid abnormalities. Lupus activity can be measured 
using validated tools such as BILAG but how this corresponds to cytokine activity 
especially as assessed by serum levels is complex. The author collected data regarding lipid 
profiles, BILAG assessment and serum IL-1 and TNF-alpha levels from these patients. 
 
As for clinical consequences in SLE patients with hyperlipidemia, the outcomes of the 100 
Singaporean patients were assessed at five years. These were young patients and any 
clinical atherosclerotic event at a young age would be significant, assuming there were no 
other contributing factors such as vasculitis or the anti-phospholipid syndrome.  
 
As a result of clarifying these issues, a treatment strategy can be devised to lessen the 








The candidate performed a study (25) at Tan Tock Seng Hospital to determine the extent of 
the problem of dyslipidemia in Singaporean patients with SLE. This hospital receives 
nation wide referrals from general practitioners and other specialists. Fasting lipid profiles 
were measured in 100 consecutive patients with SLE hospitalised or attending the 
outpatient clinics over a two month period from September to November 1990. Informed 
consent was given. Serum total cholesterol (TC), high density lipoprotein (HDL) and serum 
triglyceride (TG) were assayed using the Kodak Ektachem analyser and Kodak Ektachem 
clinical chemistry slides for TC, HDL and TG. This is an enzymatic method using 
multilayered film elements for analysis. Low density lipoprotein (LDL) and TC/HDL ratios 
were calculated. Biodata noted for each patient were age, gender, race, presence of diabetes 
mellitus, hypertension, thyroid disease, familial hyperlipidemia, smoking history, renal 
involvement as defined by the revised 1982 ARA criteria for SLE, ie proteinuria greater 
than  0.5 g per day or the presence of cellular casts; active disease was defined by the Lupus 
Activity Criteria Count (LACC) (26) ; the presence of nephrotic syndrome, previous and 
current use of anti-hypertensive agents, duration of SLE to the nearest month, the 
cumulative dose of steroids since diagnosis and current dose of steroids. History of any 
previous clinical events related to atherosclerosis such as myocardial infarction and/or 
stroke was also noted. Patients who fulfilled at least four criteria of the 1982 revised criteria  
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 for SLE were recruited. The definition of a normal lipid profile followed guidelines of the 
National Cholesterol Education Programme (NCEP) published in 1988. Most of our 
patients had less than 2 of the following cardiac risk factors, ie hypertension, diabetes 
mellitus, smoking, familial hyperlipidemia and family history of coronary artery disease. 
Comparison of means was done using Student’s t test and proportions were tested using the 
chi square or the chi square for trend. The effect of SLE activity, renal disease, age, current 
prednisolone dose and use of lipid interfering agents on lipid profiles were assessed using 
the multiple linear regression analysis (ANCOVA test). 
 
The candidate also studied a cohort of SLE patients with age and gender matched controls 
from the same region in the UK with regards to lipid profiles (27). One hundred patients 
with SLE were recruited from the Royal National Hospital for Rheumatic Diseases, Bath, 
UK. They  fulfilled at least 4 of the 11 criteria of the 1982 ARA Revised Criteria for SLE. 
Clinical data relevant to dyslipidemia were obtained: age, gender, history of smoking and 
alcohol intake, relevant family history, usage of corticosteroids, anti-malarial drugs and 
anti-hypertensive agents, past history of diabetes mellitus, hypertension, ischemic heart 
disease, stroke, peripheral vascular disease, body mass index, waist-hip ratio and diet 
questionnaire. Disease activity was assessed using the British Isles Lupus Assessment 
Group (BILAG) score. Laboratory markers of activity (serum C3, C4, anti-dsDNA, ESR, 
CRP) and serum cytokine levels (IL-1, IL-6, TNF alpha) were measured. Fasting blood  
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 samples were taken for measurement of lipid profiles comprising VLDL, HDL, TG, Lp(a), 
apo-B100 and apo AI and postheparin lipolytic activity. The lipid profiles were obtained 
through ultracentrifugation and chromatography. 
 
An attempt was made to measure lipoprotein lipase activity by doing a postheparin 
measurement of lipolytic activity. Heparin was given to the patient and blood samples were 
obtained at the time of heparin injection and thirty minutes later. Total lipolytic activity was 
measured using a chromatography procedure.  
 
In the Bath cohort, the lipid profiles of SLE patients and their age and gender matched 
controls were compared. The patients with active lupus as assessed by BILAG were 
compared to their age and gender matched controls. Simliarly those with inactive lupus 
were also compared to their own controls. This is to observe differences if any in the 
different lipid subfractions in active versus inactive lupus. Serial data involving lupus 
activity, cytokine levels and lipid profiles will also yield useful information.  
 
As for assessing consequences of hyperlipidemia in SLE, the records of the original 100 
Singaporean SLE patients were traced after five years. Contact tracing was attempted for 
those who had defaulted. In the review of casenotes, attention was paid to capturing causes 
of death, new lupus manifestations, complications of treatment or illness, occurrence of 





















 4 a. LIPID ABNORMALITIES IN  PATIENTS WITH SLE 
 
The Singaporean patients were divided into three groups according to their lipid profiles 
(Table 1). Group 1 comprised patients with a normal profile based on three variables 
(normal TC, TG and TC/HDL). Group 2 had abnormalities in 1 or 2 of the 3 variables. 
Patients in Group 3 had abnormalities in all 3 variables. LDL was not used as a criterion in 
this study because it was calculated by the Friedewald formula which becomes inaccurate 
in the presence of marked hypertriglyceridemia, which was found in a substantial number 
of our patients. There were 27 patients in Group 1, 38 in Group 2 and 35 in Group 3. 
 
Compared to Group 1, after adjustment for age, use of beta-blockers, diuretics and current 
prednisolone dose, Group 3 had higher mean TC  (355 mg/dl, SE 18.1 vs 190 mg/dl, SE 
20.3, LDL (233 mg/dl, SE 13.6 vs 95 mg/dl, SE 15.6), TG (354 mg/dl, SE 32.9 vs 127 
mg/dl, SE 37), TC/HDL (7.8, SE 0.7 vs 3.1, SE 0.8) and lower HDL (51 mg/dl, SE 3.6 vs 68 
mg/dl, SE 4.1).  Less prominent but statistically significant differences were also found in 







Table 2 shows the characteristics of these patients. Although there were more men in Group 
3, the difference was not statistically significant. The mean age was similar as was the racial 
distribution. The majority were Chinese. The number of patients receiving 
hydroxychloroquine, having diabetes mellitus, hypothyroidism, coronary heart disease and 
familial hyperlipiemia did not differ significantly among the 3 groups. Sixteen patients in 






















Group 1            Group 2            Group 3                                       p value 





















184.7 (30.9)       225.5 (64.9)       361.6 (156.3)  
190.8 (20.3)       227.1 (16.7)       355.3 (18.1)            NS              p<0.001         p<0.001 
 
93.4 (27.8)         127.2 (46.6)       236 (17.4)  
95.8 (15.6)         127.9 (12.7)       233.4 (13.6)            NS               p<0.001         p<0.001 
 
69.6 (14.9)         61.1 (26.7)        50.4 (14.9)  
68.7 (4.1)           61.1 (3.3)          51.0 (3.6)                  NS               p<0.002         p<0.05 
 
107.5 (31.1)       200.1 (88.1)      374.9 (305.6)             
127.6 (37)          204.4 (30.5)      354.7 (32.9)              NS               p<0.001         p<0.001 
 
2.7 (0.6)             4.1 (1.9)            8.2 (6.1)                    
3.1 (0.8)             4.2 (0.6)            7.8 (0.7)                     NS               p<0.001         p<0.001 
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 (U): unadjusted mean lipid indices 
(A): adjusted mean lipid indices for age, use of betablockers/diuretics and current prednisolone dose 
















                                                                                 Group 1                  Group 2             Group 3 
Characteristics                                                          (n=27)                    (n=38)                 (n=35) 
 
 
Male:Female                                                             1:26                          2:36                    7:28 
 
Age  (mean and SD)                                                33.7 (7.7)                  31.2 (9.7)            32.2 (11.7) 
Median                                                                      32                               32                        33 
 
Race (%) 
Chinese                                                                   25 (92)                       32 (84)               28 (80) 
Malay                                                                       1 (4)                           4(10)                  5 (14) 
Indian                                                                       1 (4)                           1 (3)                   0 (0) 
Others                                                                       0 (0)                           1 (3)                   2 (6) 
 
History of 
Diabetes mellitus                                                      0                                0                         3 
Smoking                                                                    0                                0                         0 
Familial hyperlipidemia                                          0                                0                         0 
Hypertension*                                                          5                                9                       12 
Family history of CAD**                                        0                                0                         0 






* Only 2, 4 and 10 patients in Group 1, 2 and 3 respectively were taking diuretics or beta blockers. The 
emainder were taking calcium channel blockers or methyldopa. 






















This study showed that dyslipidemia is common in a fairly severe cohort of Singaporean 
SLE patients. There was no attempt made to compare differences in dietary intake and this 
may have been a confounding factor. Nonetheless, the degree of the hyperlipidemia in the 
35 patients were of the extent that they were unequivocally high compared to population 
norms. The mean total cholesterol was 361 mg/dl, LDL-C was 236 mg/dl, HDL-C was 50.4 
mg/dl, TG was 374 mg/dl and TC/HDL ratio was 8.2. These patients have a mean age of 32 
and the risk of premature atherosclerosis is a real one. 
 
Although 100 patients were recruited for the study in Bath, only 64 patients and 64 matched 














Lipid Profiles of 64 British SLE patients versus age and gender matched controls 
 
     SLE     Control  p value 
n=64   n=64 
Cholesterol 
TC mean (SD)    197.3 (45.6)  207.5 (50.3)  NS 
VLDL     17.9 (10.1)  18.7 (12.1)  NS 
LDL     134.9 (37.4)  140.8 (47.2)  NS 
Total HDL   44.5 (13.7)  47.9 (15.2)  NS 
HDL 2    17.5 (10.1)  21.8 (10.1)      0.023 
HDL 3    26.1 (8.2)  25.7 (10.9)  NS 
Triglycerides 
Total TG   107.1 (47.8)  108.8 (53.9)  NS 
VLDL    33.6 (26.5)  34.5 (31.9)  NS 
LDL    49.6 (25.7)  58.4 (30.1)  NS 
HDL    19.5 (18.6)  19.5 (21.2)  NS 
Apo A1    120.23 (27.4)  142.84 (28.9)  0.0001 
Apo B     64.15 (21.04)  69.74 (22.32)   NS 
 




The Bath and Singapore cohorts were not studied at the same time and were not designed 
for direct comparison. Nonetheless there were interesting differences in the two cohorts  
 
In the earlier predominantly Oriental population of 100 SLE patients, the candidate found 
that 35 had a Type IIb hyperlipidemia with a raised mean total cholesterol level of 361 
mg/dl, LDL of  236 mg/dl, HDL of 50.4 mg/dl and triglyceride level of 354 mg/dl. These 
levels are very grossly abnormal compared to the mean values of the Singaporean 
Chinese population.  
 
In contrast, in this cohort of Caucasian SLE patients at Bath, UK,  it was found that 
compared to age and gender matched controls, the patients did not have grossly different 
lipid abnormalities except for a significantly lower  HDL 2 subfraction and also lower 
apoprotein A I. Interestingly, HDL2 was lower but not HDL3. One possible explanation of 
this differing pattern of lipid abnormalities may be explained by the fact that the Bath 
cohort generally represented a milder subset of lupus. Only 6% of the Bath patients had 
renal involvement and only 46% were on corticosteroids. In contrast, 60% of the Singapore 
patients had renal involvement and 97 % were on oral corticosteroids. 
 
The nephrotic syndrome and corticosteroid usage both tend to produce a Type IIb pattern 
and hence in the Singapore cohort this was the more obvious abnormality.  In the Bath 
cohort, the effects on LDL and triglyerides were negligible. This is despite the fact that the  
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cohort was older than the Singaporean cohort in which case one would have expected more 
lipid abnormalities.  
 
Therefore hyperlipidemia is common in the subset of SLE patients in whom renal 
involvement is common and steroid usage is relatively high. The pattern of hyperlipidemia 
is a Type IIb whereas in a cohort of milder patients with little renal involvement and low 



































 5 a) Corticosteroids 
 
As mentioned earlier, possible mechanisms of hyperlipidemia are many but three 
mechanisms are explored in this thesis, namely the use of corticosteroids, the presence of 
renal disease and the extent of lupus activity. 
 
With regards to corticosteroid use, there were no differences in the mean duration of illness 
and mean cumulative dose of prednisolone in the three groups of Singaporean patients  with 
differing lipid profiles (Table 4). However, the mean current daily prednisolone dose in 
Group1 and Group 3 were 9 and 23.5 mg respectively (p<0.001). Patients taking more than 
30 mg of prednisolone a day had higher mean TC, LDL, TG and TC/HDL but lower HDL 
compared to those taking less than 30 mg a day. This data is presented in Table 5. 
 
In the Bath cohort, steroid usage was very low as only 46% of the patients were ever on 
steroids. Compared to age and gender matched controls there were no differences in TC, 
LDL and TG levels. This provides indirect evidence that corticosteroid usage gives rise to 




 Table 4.  Clinical variables of 100 Singaporean SLE patients 
 
                                                            Group 1           Group 2          Group3                 chi-sq for trend 
                                                             (n=27)              (N=38)           (N=35) 
 
Duration of illness (months) 
Mean (SD)                                        68 (60.9)           90 (35.6)          68.1 (65.7)           NS 
Median                                                48                    40                       50 
 
Renal disease 
Renal/Total                                          10/27                23/38               27/35                   p<0.001 
Nephrotic/Total                                   0/27                  4/38               12/35                     ND* 
Nephrotic/Renal                                  0/10                  4/23                12/27                      ND* 
 




Diuretics/betablockers                        2/27                 9/38                 10/35                     NS 
Prednisolone 
Nil                                                         1/27                 1/38                   1/35                   NS 
Mean current dose (mg)                      9 (11.8)          15 (16.4)           23.5 (18.7)         p<0.001 
Cumulative dose (g)                          20.5 (25.5)       19.7 (18.2)         23.8 (21.6)         NS 
Hydroxychloroquine                                1/27                1/38                   0/35               ND* 
ND: not done, as each group has a cell where there are no patients 
       U: Unadjusted mean lipid indices 
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A: Adjusted mean lipid indices for age, current prednisolone dose and use of betablockers and diuretics 
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Table 5.  Effect of corticosteroids on lipid profiles 
 
 
Mean Lipid                            Prednisolone                        Prednisolone 
Indices                                      <30 mg/day                        >30 mg/day                   p value 
Mean (SD)                                (n=81)                                   (n=19) 
 
TC (U)                                    247.9(95.6)                          322.6(204.6)  
(A)                                               247.9                                    322.9                          p<0.05 
 
LDL (U)                                  146.9(81.7)                           198.5(140.8)   
(A)                                           146.9                                     198.4                               p<0.05 
 
HDL (U)                                  62.1(20.5)                          49.0(22.7)                    
(A)                                           62.2                                    48.3                                   p<0.05 
 
TG (U)                                   204.7(133.5)                         370.8(394.9)  
(A)                                          202.6                                     380                                 p<0.05 
 
TC/HDL (U)                        4.5(2.8)                                  8.2(7.9)  
(A)                                        4.4                                         8.4                                   p<0.05 
 
 
U: Unadjusted mean lipid indices 
A: Adjusted mean lipid indices for age and hypertension 
NB: No adjustment was made for activity of SLE and renal status because majority of patients with active SLE 
and renal disease took >30 mg prednisolone per day 
 
 
 We found that the use of corticosteroids was associated with the abnormal lipid profiles. 
Patients taking more than 30 mg of prednisolone a day had higher mean TC, LDL, TG and 
TC/HDL but lower HDL compared to those taking less than 30 mg a day. Most of these 
patients were on corticosteroid therapy as they generally had more severe lupus disease. 
The mean current daily dose of those with normal lipid profiles was 9 mg whereas it was 
23.5 mg in those with abnormal lipid profiles (p<0.001).  These findings are consistent with 
several previous studies which show that the use of systemic corticosteroids is associated 
with lipid abnormalities. Corticosteroid therapy has been shown to produce abnormal lipid 
profiles including high serum triglycerides, high LDL cholesterol and decreased HDL 
cholesterol. Ettinger and Hazzard (28) confirmed this in a study on 28 women with SLE 
treated with corticosteroids, comparing them with 10 women with SLE not taking steroids 
and 15 normal women. He found that the prednisone treated group had higher mean plasma 
triglyceride levels, higher LDL cholesterol and higher apolipoprotein B levels than the 
other two groups. 
 
In this Singaporean cohort of patients with fairly severe lupus disease, the use of 
corticosteroids contributed significantly to hyperlipidemia. Therefore, in such patients, this 





 5 b)  Renal Disease 
 
In the Singapore study, we found that there were 27 out of 35 patients with the most 
abnormal lipid profiles had renal involvement (ie high TC, low HDL, high LDL, high TG) 
versus 10 out of 27 in the group with normal lipid profiles (p<0.001). Therefore it seems 
that the presence of renal involvement is associated with abnormal lipid profiles. This was 
renal involvement as defined by the 1982 ARA Criteria for the diagnosis of systemic lupus 
erythematosus rather than the presence of the nephrotic syndrome. Out of the 27 with renal 
involvement in the abnormal lipid group, 12 had the nephrotic syndrome but none of the 10 
in the normal lipid group were nephrotic. This however did not reach statistical significance 
on analysis, perhaps because of small numbers. Nonetheless, the trend suggests the 
importance of the nephrotic syndrome in contributing to abnormal lipid profiles in this 
group of patients. The impact of nephrotic syndrome on lipid profiles has been well 
documented in other renal diseases such as primary glomerulonephritis. 
 
In this Singaporean SLE cohort, renal involvement is common and occurs in 60% of our 
patients. Many of these patients have the nephrotic syndrome. This contributes 
significantly to their risk of persistent hyperlipidemia and premature atherosclerosis. When 
Group I and Group 3 were compared, significant differences were found in the proportion 
of patients with renal involvement (p<0.001). Two patients in Group 3 had clinical events 
related to hyperlipidemia. One had myocardial infarction at age 29 and the other had renal 
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infarction at age 30. There was no evidence of vasculitis or antiphospholipid syndrome in 
these 2 patients. Their anticardiolipin antibody and lupus anticoagulant were negative. 
 
Among the 64 patients with inactive SLE (LACC score of <2), those with renal 
involvement had higher mean TC, LDL, TG and TC/HDL but no difference in HDL 
compared to those without renal involvement (Table 6). 
 
In the Bath study, only 6% had renal involvement and therefore the patients did not have 















 Table 6.   Lipid Profiles in Different Clinical States 
 
 
Lipid Indices                      Non-renal (n=42)                                        Inactive disease (n=64) 
Mean (SD)                Active (n=11)      Inactive (n=31)     p       Renal (n=33)      Nonrenal (31)     p 
 
TC (U)                      244.7(98.3)           209.5(51.5)                    264.1(111.9)        209.5(51.5)  
(A)                            197.8                     226.2               NS        263.6                    210.1                p<0.05 
 
LDL (U)                   141.2(91.9)            116.5(43.9)                    164.3(99.5)          116.5(43.9)  
(A)                             93.8                      133.3                NS        165.9                    114.7                p<0.05 
 
HDL (U)                     49.8(18.6)            64.1(16.3)                       63.6(24.1)             64.1(16.3)        
(A)                             53.1                       62.9                    NS        62.7                       65.0                NS 
 
TG (U)                     266.9(133.5)           142.9(77.6)                    208.2(111.2)        142.9(77.6)  
(A)                            246.8                       150                  NS        204.6                    146.7               p<0.05 
 
TC/HDL (U)               5.6(4.1)                  3.4(1.1)                         4.8(3.5)                3.4(1.1)          






 5 c)  Active SLE 
 
In SLE patients, dyslipidemia is linked to the presence of renal disease and high doses of 
corticosteroids.  Lipid abnormalities may also be linked to the presence of active SLE. 
 
In the Singapore study, when Group I and Group 3 were compared, significant differences 
were found in the proportion of patients with active SLE (p<0.001) (Table 4). 
 
In the subgroup of 42 patients without renal involvement, those with active SLE had lower 
mean HDL-C, higher mean TC, LDL-C, TG and TC/HDL when compared to those with 
inactive SLE (Table 6). However, the differences did not reach statistical significance after 
adjusting for age, use of beta blockers, diuretics and prednisolone. Nonetheless, this 
suggests that active SLE per se may have an influence on lipid profiles. In this study, the 
Lupus Activity Criteria Count was used as a measure of lupus activity. At the time of the 
study, the newer assessment tools such as BILAG (British Isles Lupus Activity Assessment 
Group) (32), SLAM (Systemic Lupus Activity Measurement) (33) and SLEDAI (Systemic 
Lupus Erythematosus Disease Activity Index) (34) were not in use yet.  
 
This pattern of lipid abnormalities could be due to the effect of cytokines on lipid 
metabolism. Cytokines, in particular IL-1 and TNF-alpha have been shown to suppress 
lipoprotein lipase synthesis and activity in-vitro. This would lead to a Type IV dyslipidemia 
similiar to that which is found in some diabetic patients. This form of dyslipidaemia is not 
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likely to be innocuous although the data supporting its clinical role is not as substantial as 
that which is available for LDL and Lp(a). Pathogenicity may reside with an abnormal 
VLDL particle and this can be tested for by lipoprotein subfractionation and analysis. 
 
It is possible that active SLE causes a Type IV dyslipidemia via the suppression of 
lipoprotein lipase as cytokines such as IL-1 (Interleukin-1) and TNF-alpha (Tumour 
necrosis factor alpha) are upregulated. Studies in active rheumatoid arthritis show a Type 
IV dyslipidemia compared to inactive RA but few studies have tried to establish a link 
between active rheumatic disease, upregulation of cytokines, suppression of lipoprotein 
lipase and a Type IV dyslipidemia. 
 
In the Bath cohort, because of the low rate of renal disease and the infrequent use of 
systemic corticosteroids, it was a good opportunity to study the effects of active lupus 
activity per se on hyperlipidemia. 
 
There were logistic difficulties with the post heparin lipolytic challenge and also the 
availability of serial data. Therefore data involving cytokine profiles, serial BILAG and 
lipoprotein lipase activity both cross sectionally and longitudinally were incomplete and 
may not be subject to stringent analysis.  Nonetheless, the trends may give some idea of the 
complexity of the problem. 
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 There was however complete data collection with regards to detailed lipid profiles in  sixty 
four patients versus their age and gender matched controls, as presented in Table 3. Forty 
six patient had complete lipid profiles with matched controls as well as BILAG assessment 
done. Of these 33 were inactive and 13 were active. When the active patients were 
compared to controls, the patients had lower total HDL, lower HDL2, lower apoA and 
higher TC/HDL ratio. When compared to matched controls, the patients who did not have 
active disease showed a different pattern. These patients had lower TC, lower LDL, lower 
total HDL, lower HDL2, lower apoA and lower apoB. (Table 7) 
 
In nine patients there was complete data on serial BILAG assessment, serum lipid levels 
and cytokine profiles (TNF alpha and soluble IL2 receptor). This is presented in Tables 8 
and 9. Serial assessments were done 6 months apart. Of the nine patients, four had inactive 
SLE as measured by BILAG in both visits and five patients went from active to inactive 
SLE.  
 
In these patients followed up serially, soluble IL2-R and BILAG generally correlated as 
markers of lupus activity. Out of the nine patients, serial sIL2R decreased in seven. Of these 
seven, four progressed from active to inactive lupus on BILAG and the other three 
remained inactive at both visits. In all of the seven patients in whom sIL2R decreased, there 
was an increase in apoprotein A I.  
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There were no differences in serum levels of IL-1 and TNF-alpha between patients with 
active and inactive SLE. The numbers are really too small to make any definite conclusions. 
However a possible reason for the lack of correlation is that serum cytokine levels do not 
reflect perfectly changes in cytokine regulation at the cellular level. Hence the use of serum 
cytokines to monitor lupus activity may not be useful and may not add significant 
information that is useful clinically. 
 
Another reason may have to do with BILAG score (British Isles Lupus Activity Group) 
being applied to a patient population where the change in lupus activity is small. The 
BILAG is a validated tool for assessing lupus activity and comprises clinical as well as 
laboratory parameters. It is thought to be more sensitive change compared to other tools 
such as SLAM (Systemic Lupus Activity Measurement) and SLEDAI (SLE Disease 
Activity Index). However in the British cohort, the patients had generally mild lupus and 
low lupus activity. Therefore the changes in their lupus activity over time was also not very 
significant and could not be detected with serial use of BILAG. 
 
We measured lipoprotein lipase by a post-heparin lipolytic activity (PHLA) assay and also 
levels of hepatic lipase. In cross-sectional analysis, we were unable to detect differences in 
either PHLA or hepatic lipase between patients with active and inactive SLE. This could be 
due to PHLA being an imperfect measure of lipoprotein lipase. The numbers of patients in 
the two groups may have been too small to pick up significant differences and some were 




 Other evidence to support this hypothesis was difficult to obtain in the Bath study because 
of incomplete data collection from logistic difficulties. As a result, we failed to establish a 
link between active SLE, upregulation of cytokines, suppression of lipoprotein lipase and 
the resulting lipid abnormalities. 
 
Nonetheless, we found a pattern of low  HDL2 and apoprotein AI compared to age and 
gender matched controls. This is consistent with a suppression of lipoprotein lipase. As 
mentioned earlier, lipoprotein lipase is suppressed by pro-inflammatory cytokines such as 













 Table 7 
 
 
  Active n=13    Inactive n=33 
 
 Patient Control    p       Patient     Control        p 
TC       214.1 (54.9)    211.4 (52.3)      NS         195.8 (42.9)   241.0 (45.2)    <0.0001 
VLDL   20.9 (13.3)       18.3  (7.0)      NS             18.3    (8.9)    19.9 (13.3)       NS 
LDL      150.9 (46.4)   140.8 (52.7)      NS            130.3 (33.5)   165.8 (45.6)     0.0003 
HDLT   43.3 (10.1)      53.4 (14.8)      0.03            46.4 (15.2)     52.7 (15.2)       0.05 
HDL2    14.0 (7.8)        23.8 (10.9)      0.009          19.9 (11.3)     24.9 (12.5)       0.05 
HDL3    28.9 (10.9)      30.0 (6.2)        NS             26.5 (7.4)       27.7 (7.0)          NS 
TC/HDL 5.12 (1.43)     4.15 (1.46)      0.05          4.62 (1.8)       4.95 (1.83)       NS 
Apo A     117.8 (21.7)   137.4 (23.7)    0.02          120.4 (27)      153.7 (40.2)       0.0003 
Apo B      69.5 (24)          73 (28)          NS            63.6 (15.7)      80.8 (27.9)      0.002 






Table 8   Serial Data on four patients who had inactive lupus on both visits  
 
   Patient 1  Patient 2 Patient 3 Patient 4 
1st  Total HDL            67.1   60.1  25.7  35.9  
2nd Total HDL    54.9   28.5  32.8  37.8 
1st  HDL2   37.1   21.5  8.9  10.5 
2nd HDL 2   38.2   9.8  14.8  19.1 
1st ApoA I             138   141  77  101 
2nd ApoA I  143   161  88  100 
1st TC   198.9   295.2  134.5  147.8 
2nd TC   167.3   283.1  105.3  132.6 
1st LDL                              173.2   219.9  91.7  95.9 
2nd LDL  106.5   239.1  62.8  95.9 
1st TG   61.1   59.3  74.3  76.1 
2nd TG   66.4   82.3  27.4  68.1 
1st VLDL  16.8   15.2  17.2  15.9 
2nd VLDL  5.8   15.6  9.8  4.3 
1st TNF alpha               21   12  15  3 
2nd TNF alpha  19   6  12  12 
1st sILR   2800   1550  1170  2280 




 Table 9 
 Serial data on five patients who had active disease on the first visit and inactive 
disease on the second 
 
Patient 1 Patient 2 Patient 3 Patient 4  Patient 5 
1st  Total HDL            45.6  50.7  33.5  30.8  34.3  
2nd Total HDL    38.6  57.3  37.8  35.9  40.2 
1st  HDL2  16.4  33.5  10.9  8.2  8.9 
2nd HDL 2  23.4  10.1  17.2  7.4  6.2 
1st ApoA I             107  125   89  94  104 
2nd Apo A I  116  151  114  112  122 
1st TC   141.9  242.6  165.8  190.7  229.7 
2nd TC   136.9  235.6  143.1  205.5  257.0 
1st LDL    88.9  173.6  118.6  131.4  161.5 
2nd LDL  90.9  157.2  93.6  135.7  180.2 
1st TG   49.6  113.3  71.7  115.1  140.7 
2nd TG   53.9  139.8  48.5  146.0  150.5 
1st VLDL  7.4  18.3  11.3  24.9  33.9 
2nd VLDL  7.4  21.1  15.9  33.9  36.7 
1st TNF alpha  20  11  10  15  13 
2nd TNF alpha  19  11  15  14  13 
1st sIL2R  1150  480  1330  1220  3200 








7 What could be the clinical consequences of 










 6 a) OUTCOME OF SLE PATIENTS WITH 
HYPERLIPIDEMIA AFTER FIVE YEARS 
 
In the earlier study referred to where 100 SLE patients had lipid profiles measured, the 
candidate did a chart review of these same patients after five years (35). At that time, only 
notes from 94 patients were available. Of these 94, 7 had emigrated or defaulted follow up. 
Therefore, we were only able to analyse casenotes from 87 of the original 100 patients, a 
dropout rate of only 13 % over 5 years. Contact tracing was attempted for the missing 13 
patients but was unfruitful 
.  
When they were first recruited in 1990, the mean age was 32 years, mean duration of illness 
was 60 months and mean cumulative dose of corticosteroids was 20 g. Sixty percent had 














Of the 87 patients, 13 perished. This gives a five year survival rate of 85%. However data 
was not available for 13 out of the original 100 patients. Hence the true figure for five year 
survival ranges from 74% to 87%. 
 
Six deaths were lupus related, five were due to infection and two were due to neither. Of the 
lupus related deaths, two deaths were from CNS lupus, one from end stage renal failure, one 
from lupus gut, one from pulmonary haemorrhage and one from pulmonary hypertension. 
Duration of illness before death ranged from 3 to 15 years. Three deaths occurred within the 
first five years of diagnosis. All six patients had Class IV lupus nephritis. 
 
Of the infection related deaths, two had pyogenic infection, one had pneumocystis carinii 
pneumonia, one had disseminated atypical mycobacterial infection and one had fulminant 
septicemia. Duration of illness before death ranged from 3 to 13 years. 
 





 Of the 87 patients, 19 had new lupus manifestations in the five years of study. Seven 
developed lupus nephritis while on follow up, six of which were biopsy proven. Three of 
these were Class IV. Other new lupus manifestations included myositis, vasculitis, 
seizures, subacute cutaneous lupus, autoimmune hemolytic anemia, lupus panniculitis, 
thrombocytopenia, the antiphospholipid syndrome, transverse myelitis and pulmonary 
hypertension. 
 
Six patients developed end stage renal failure requiring dialysis as a result of worsening 
lupus nephritis. Twenty-two patients had complications judged to be related to treatment of 
lupus rather than the illness. Seven had avascular necrosis of the hip, three had cataracts, 
infections occurred in ten and two patients, aged 35 and 45 developed ischemic heart 
disease. Duration of lupus at the time of detection of ischemic heart disease was ten years in 
one and twenty years in the other. Both had persistent hyperlipidemia contributed by 
recurrent nephrotic syndrome and prolonged use of systemic corticosteroids. Neither had 











In this study on morbidity and mortality of SLE in a severe subset, there was a five year 
survival of 85%. Of the 13 deaths, six were lupus related, five were from infections and two 
were due to malignancy, one a carcinoma of the ovary and the other a teratocarcinoma. The 
lupus related deaths were in a younger age group (mean age of 20) compared to the mean 
age of 32 in the whole cohort. All 6 had Class IV lupus nephritis. The infections tended to 
occur later in the illness, most of them after the fifth year of illness. 
 
Hence lupus related deaths tend to occur early on in the illness particularly in those with 
poor prognostic factors such as the presence of Class IV nephritis and a young age of 
onset. Infections usually occur as a complication of immunosuppressive treatment and 
hence occurs a little later on in the course of the illness.  Presumably deaths could also 
occur as a result of premature atherosclerosis but this may only occur perhaps even later on 
in the illness and hence did not show up in this study which looked at a five year outcome. 
Our cohort was also generally young with a mean age of 32 and this again makes it more 
difficult to pick up mortality from premature atherosclerosis if the duration of follow up is 
too short. 
 
However, there were two patients who suffered myocardial infarction at the ages of 35 and 
45 respectively. Both had hypertension and hyperlipidemia and were negative for 
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anticardiolipin antibody and lupus anticoagulant. There was no clinical evidence of 
systemic vasculitis. The presence of these events in two out of 100 such young patients 
confirm the need for vigilance in addressing the potential problem of hyperlipidemia and 















































 THE IMPORTANCE OF HYPERLIPIDEMIA IN SLE 
 
SLE is a potentially devastating illness that afflicts young women in their most productive 
years and thankfully, outcomes of treatment have been improving over the years (36). The 
consequence of this however is that, although patients with SLE now live longer, they are 
more likely to develop complications related to treatment side effects. These include many 
of the evils of prolonged corticosteroid therapy as well as side effects from some 
manifestations such as recurrent, persistent nephrotic syndrome and vasculitis. 
Corticosteroid induced osteoporosis can lead to fragility fractures in a subset of women and 
avascular necrosis of the hips and rarely other bones. Arthroplasty may be necessary at an 
early age. Premature cataracts can occur with chronic corticosteroid use. Infertility and 
early amenorrhoea is associated with the use of certain immunosuppressive agents and life 
threatening infections can be a problem. 
 
One of the more potentially life threatening complications in SLE patients is premature 
atherosclerosis. In 1976, Urowitz et al (37) recognized a bimodal pattern in the morbidity 
and mortality of SLE with early events due to active disease or infections and late events 
related to atherosclerotic complications. From that study it was unclear whether this was 
linked to hyperlipidemia or to other factors.  Petri et al (38) studied prospectively the risk 
factors for coronary artery disease in 229 SLE patients. Nineteen patients (8.3%) had 
coronary artery disease and accounted for 3 out of 10 deaths in this cohort. The most 
significant factors using a best multiple logistic regression model were age at diagnosis, 
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duration of prednisone use, requirement for anti-hypertensive treatment, maximum 
cholesterol level and obesity. 
 
Many studies including some involving autopsies have shown premature coronary 
atherosclerosis and myocardial infarction in relatively young patients with SLE. Bulkley 
and Roberts (39) compared necropsy findings of 36 SLE patients with findings in patients 
who were not on corticosteroids. Subepicardial and myocardial fat was increased in all 36 
patients. In 42% of the 18 patients who received corticosteroids for more than one year, the 
lumen of at least one of the three major coronary arteries was narrowed by more than 50% 
by atherosclerotic plaques. In contrast, none of the 17 patients who received corticosteroids 
for less than one year had such findings. 
 
Besides causing atherosclerotic clinical events, hyperlipidemia has increasingly been 
recognized to worsen renal prognosis in patients with various forms of glomerulonephritis 
(40). The nephrotic syndrome causes hyperlipidemia which in turn causes a degree of 
damage to the mesangium. A stark example of the impact of the combination of steroids 
and the nephrotic syndrome was the case report of the  death of a five year girl two years 
after onset of nephrotic syndrome which was refractory to corticosteroid and 
cyclophosphamide therapy. Severe atherosclerotic changes were noted in her coronary 
arteries (41).  
 
In SLE patients, the traditional risk factors for atherosclerosis such as hyperlipidemia, 
hypertension and age are important. However, there are also some non traditional risk 
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factors that have been shown to be important as well and these are linked to the illness 
itself. Roman et al (42) studied 197 SLE patients with 197 matched controls. Carotid 
ultrasonography and echocardiography were used in the evaluation. Atherosclerosis 
(carotid plaque) was more prevalent among patients (37.1% vs 15.2 %, p<0.01). In 
multivariate analysis, only older age, higher serum cholesterol and presence of SLE (odds 
ratio 4.8, confidence interval 2.6 to 8.7) were independent risk factors for the presence of 
plaque. Among SLE patients, independent predictors of plaque were a longer duration of 
illness, a higher damage-index score, a lower incidence of the use of cyclophosphamide and 
the absence of anti-Smith antibodies. This study shows that atherosclerosis in SLE patients 
are related not just to traditional risk factors for cardiovascular disease. Disease related 
factors play an important role too. 
 
If significant hyperlipidemia exists in SLE patients, it has to be treated as it would be a 
tragedy for a lupus patient for whom life threatening lupus disease is averted, to die from an 
atherosclerotic clinical event linked to hyperlipidemia.  
 
Therefore, some important questions need to be answered: 
1) How common is hyperlipidemia among SLE patients? 
2) What are the risk factors for hyperlipidemia in SLE patients? 
3) What are the consequences of hyperlipidemia in these patients? 
 
This thesis tries to address these three questions. As a result of these questions being 
clarified, the next step would be to explore treatment options in these patients with regards 
 69
to hyperlipidemia. Proof of whether earlier detection and treatment of hyperlipidemia 
would lead to improved outcomes would only be available through subsequent large 






















 HOW COMMON IS HYPERLIPIDEMIA AMONG SLE PATIENTS? 
 
In the study published in Journal of Rheumatology, the candidate recruited 100 
Singaporean SLE patients in a cross-sectional study. These patients were typical of the 
severe spectrum seen in the Dept of Rheumatology and Immunology which is a tertiary 
centre for management of such patients in Singapore. This is reflected by the fact that 60% 
had renal involvement and cumulative dose of prednisolone at the time of recruitment was 
20 g. 
 
It turns out that 35% had the worst possible lipid profiles with raised TC, LDL, TG, 
TC/HDL ratio and low HDL. Although there were no age and gender matched controls in 
this study, the mean values in this group are grossly abnormal compared with values in the 
general population. The mean TC was 355 mg/dl , LDL-C 233 mg/dl, HDL-C 51 mg/dl, TG 
354 mg/dl, TC/HDL ratio 7.8. One must remember that these were all females with a mean 
age of only 32. In the 1998 Singapore Health Survey out of 1558 Chinese women with a 
mean age of 37.8, the mean total cholesterol was 214 mg/dl LDL 130, HDL 62, TG  104 
mg/dl. (43)  This pattern of hyperlipidemia can be more of a problem in those who have 
more severe lupus disease as they are exposed to more corticosteroids, more likely to have 
nephritis and the nephrotic syndrome and have more active lupus disease.  
 
The SLE studies in Singapore and Bath cannot be used in direct comparison because they 
were not conducted at the same time and had different methodology and aims. Nonetheless 
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some interesting differences between these two cohorts can be observed. The cohort of 
patients in the Bath study did not show the same pattern of lipid abnormalities. In this 
cohort they had a much lower prevalence of renal lupus and they were on much lower doses 
of corticosteroids. Although they were older patients they did not have abnormal LDL or 
TG. They instead had low HDL and apoprotein A1 compared to age and gender matched 
controls. This could be possibly explained by the fact that pro-inflammatory cytokines are 
upregulated in SLE and these in turn depress lipoprotein lipase giving rise to low HDL. 
Similar abnormalities have been found in other autoimmune diseases. It is well known that 
tumour necrosis factor, IL1 and IL6  decrease lipoprotein lipase mRNA levels, synthesis 
and activity (44-6). In a study of patients with cystic fibrosis (47) , plasma TNF alpha was 
increased when compared with controls. The patients had lower total cholesterol, LDL and 
HDL but higher TG. ApoA1 and postheparin lipolytic activity were lower.  
 
There is ample evidence that prolonged lipid abnormalities lead to premature 
atherosclerosis and the subsequent clinical events of stroke and coronary heart disease. The 
study showed that hyperlipidemia is a common phenomenon in Singaporean patients with 
moderate to severe SLE increasing the potential for atherosclerotic events to occur. These 
young patients had very high levels of LDL-cholesterol, low HDL and high TG, all of 
which is likely to predispose them to significant atherosclerotic clinical events if left 
untreated. It is important to think of hyperlipidemia in any SLE patient regardless of age, 




Although the Bath cohort was older, the patients did not have abnormal lipid profiles  
compared to their younger counterparts in Singapore. However, their pattern of abnormal 
lipids may not be all that harmless. HDL protects against cardiovascular disease.  It 
removes and transports excess cholesterol from peripheral cells to the liver for removal 
from the body and also protects LDL from oxidation and inhibits expression of adhesion 
molecules in endothelial cells, preventing monocyte movement into the vessel wall. A low 
HDL is also associated with clinical events although to a lesser extent than with LDL or 
lipoprotein (a) abnormalities. Evidence of this exists for SLE patients as well.  Sella et al 
(48) studied 82 female SLE patients  with myocardial perfusion scintigraphy and found 
abnormalities in 23 patients (23%). Their mean age was 37 and the main factors having a 
significant influence on abnormal perfusion results were lower HDL cholesterol levels, 












 WHAT ARE THE POSSIBLE RISK FACTORS FOR HYPERLIPIDEMIA IN SLE 
PATIENTS? 
 
Various patterns of hyperlipidemia may be present in a patient with rheumatic disease (49). 
Contributing factors are likely to be nephrotic syndrome when present and the prolonged 
use of corticosteroids. Some contribution could be related to active inflammatory disease 
mediated by the effect of cytokines on lipid enzymes such as lipoprotein lipase, presence of 
anti-lipoprotein antibodies, C reactive protein and other cytokines such as IL 18. 
 
In SLE patients, there are many mechanisms which can give rise to hyperlipidemia. The 




The role of corticosteroids in causing hyperlipidemia is well known (50). The pattern that 
arises from this is usually a Type IIb hyperlipidemia. This has been shown to be true in 
different types of patients. In heart transplant patients cumulative prednisone dose was the 
strongest predictor for a high total cholesterol and LDL (51).  In renal transplant patients a 
strong etiologic relationship between hypercholesterolemia and corticosteroid dose was 
found. As steroid doses were decreased, the hypercholesterolemia improved. There was a 
reduction of 13% by three years when steroid doses were less than 10 mg daily. 
 
 74
Formiga et al (52) studied 53 premenopausal SLE patients and 45 controls. An increase in 
TC, HDL3, apo A1, and apoB with decrease in HDL2 were found in the patients versus 
controls. Increased total cholesterol, LDL and triglyceride correlated well with higher 
doses of prednisolone.  
 
Doria et al (53) followed up a prospective cohort of 78 SLE patients without overt 
atherosclerotic disease for five years. At 5 years, intima thickness was measured using 
duplex carotid sonography. Patients with carotid abnormalities were significantly older, 
had higher blood pressure, higher prednisone cumulative dose and total serum cholesterol. 
In multivariate analysis, age and cumulative prednisone dose were associated with carotid 
abnormalities 
 
It would be helpful to know if there is a threshold dose above which side effects and 
problems start to arise. For example, it is generally thought that a daily dose of prednisolone 
greater than 7.5 mg a day for more than six months would give rise to significant 
corticosteroid induced osteoporosis.  For lipid abnormalities, Petri et al (54) performed a 
cohort longitudinal study involving 264 patients with SLE. In a regression model for steroid 
use, a change in prednisone dose of 10 mg was associated with a change in cholesterol level 
of 7.5 +/- 1.46 mg% and a weight gain of 5.5 +/- 1.23 pounds. In the Singaporean cohort of 
patients, we did find a correlation between daily prednisolone dose and lipid abnormalities. 
Patients taking more than 30 mg of prednisolone a day had higher mean TC, LDL, TG and 
TC/HDL but lower HDL compared to those taking less than 30 mg a day. The mean current 
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daily dose of those with normal lipid profiles was 9 mg whereas it was 23.5 mg in those 
with abnormal lipid profiles (p<0.001).  
 
The pattern of lipid abnormalities induced by corticosteroid use is strongly associated with 
the risk of clinical atherosclerotic events and it suggests to us that patients taking high daily 
doses of prednisolone should have their lipid profiles checked regularly to detect lipid 
problems early. Treatment should be started appropriately to prevent adverse outcomes. 
Other contributing factors to hyperlipidemia and atherosclerosis should also be addressed 
such as dietary adjustment, weight control, cessation of smoking and control of 
hypertension. Non-traditional factors should be considered. These include homocysteine, 
nephortic syndrome and the presence of antiphospholipid antibodies. Martinez-Berriotxoa 
et al (55) found that plasma homocysteine concentrations are higher in SLE patients than in 
healthy controls.  
 
This underlies the fact that the use of corticosteroids in SLE is a two edged sword. Besides 
the protean side effects including osteoporosis, early cataract formation, increased 
tendency to infection, hypertension, diabetes mellitus and cosmetic problems when used in 
high doses, hyperlipidemia too has to be taken into account. Therefore the onus is on the 
rheumatologist to carefully balance the risks and benefits of using corticosteroids in each 
individual patient. Steroid sparing agents should be used if a maintenance dose of steroids 
is unacceptably high. 
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The Bath cohort on the other hand had less lipid abnormalities and were on lower doses of 
steroids. Many of the patients were not on corticosteroid therapy at all. Only 6% of the  
patients had renal involvement and only 46% were on corticosteroids. The differences seen 
in the Bath cohort could be due to the milder spectrum of lupus disease and hence the 
reduced usage of oral corticosteroid therapy. The only differences when compared to 
healthy age and gender matched controls were in a lower HDL2 subfraction and lower 
apoprotein AI. This may be linked to disease activity and release of pro-inflammatory 




Another factor which causes hyperlipidemia in SLE is the presence of renal disease. This is 
important because besides causing clinical events related to vascular thrombosis, 
dyslipidemia can accelerate the progression of renal disease. The obese Zucker rat is an 
animal model that illustrates this point (56). These animals develop hyperlipidemia by the 
age of two weeks and renal injury by 16-18 weeks especially if they are fed a 
high-cholesterol diet. The use of lipid lowering therapy prevents this injury. The 
mechanism of injury is possibly through the presence of cholesterol or triglyceride rich 
VLDL particles. These particles bind to receptors on macrophages resulting in the 
formation of the foam cells which are often found in atheromatous plaques and glomeruli. 
Lipoproteins in the mesangium undergo oxidative modification and are taken up by 
scavenger receptors on macrophages and mesangial cells.  
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Furthermore, oxidized LDL is thought to play an important role in the pathogenesis of 
inflammatory disease. For example, oxidised LDL may be an important part of the 
pathogenesis of inflammation in rheumatoid arthritis. Winyard et al (57) showed that 
oxidised LDL is present in the synovial fluid of RA but not osteoarthritic patients and 
suggests a proinflammatory role for oxidised LDL in patients with rheumatoid arthritis. In 
renal disease hyperlipidemia is thought to adversely affect renal prognosis as oxidised LDL 
may worsen inflammation within glomeruli in the patients. The situation is likely to be the 
same in lupus nephritis. Luzar and Ferluga (58) reported on histological features of  two 
cases of SLE patients showing that lipids cause tissue damage in the nephron via 
mechanisms similar to the pathogenesis of systemic atherosclerosis. Hyperlipidemia was 
causally related to prominent tubulo-interstitial lipid deposits.  In a larger study by Font et 
al (59), 70 patients with lupus nephritis and 70 age and matched control SLE patients 
without nephritis were prospectively followed up for 10 years. The mean age was 35. At 
entry the lupus nephritis patients had higher prevalence of hyperlipidemia (44% vs 2%, 
p<0.001) and positive anti-phospholipid antibodies (45% vs 22%, p=0.01). At the end of 
the study, hyperlipidemia  (78% vs 27%, p<0.001) and hypertension (67% vs 32%, p=0.01) 
at study onset were found to be associated with the development of renal failure. Nine lupus 
nephritis patients and one control patient died, mainly of cardiovascular or cerebrovascular 
events and sepsis. Patients who died were more likely to have positive anti-phospholipid 
antibodies (56% vs 17%, p=0.03) and hyperlipidemia (78% vs 37%, p=0.03) at study onset 
Therefore hyperlipidemia not only causes premature atherosclerosis leading to well known 
clinical events such as stroke and myocardial infarction, it can also worsen renal prognosis. 
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The pattern of hyperlipidemia in the nephrotic syndrome is a Type II b pattern which is that 
of elevated TC, LDL-C, TG and reduced HDL-C (29). The hyperlipidemia is generally 
thought to be reversible when the nephrotic state resolves. However, many SLE patients 
remain fairly nephrotic for much of their lives in spite of treatment for lupus nephritis. 
Many patients with Class IV continue to have active nephritis even after IV 
cyclophosphamide therapy . Gunnarson et al (30) found that albuminuria and serum C1q 
predicts for findings of persistent active lupus histology at serial renal biopsy. In his study, 
6 out of 18 patients continued to have active lupus nephritis on a second biopsy. Bajaj et al 
(31) found that second renal biopsies in the Toronto Lupus clinic were done mainly because 
of increasing proteinuria. Twenty three out of fifty seven repeat biopsies showed a change 
in histology. There was significant increase in the chronicity index but decrease in the 
activity index. It cannot be assumed therefore that treatment of lupus nephritis will decrease 
proteinuria and the hyperlipidemia associated with it. Although more long term studies are 
need to determine whether treatment of persistent hyperlipidemia in the nephrotic 
syndrome would be of benefit in lowering the risk of atherosclerotic clinical events, it 
would seem reasonable that patients with renal disease should as far as possible be rendered 
normolipidemic. This will not only prevent atherosclerotic clinical events but will also to 
prevent a vicious cycle from perpetuating in the kidney where the nephrotic syndrome leads 
to hyperlipidemia which then leads to renal injury which in turn exacerbates the nephrotic 
syndrome. 
 
In our study of Singaporean patients, the presence of renal disease as defined by the 1982 
ARA criteria for SLE was associated with a risk for having hyperlipidemia. Twenty seven 
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out of 35 patients with the most abnormal lipid profiles had renal involvement (ie high TC, 
low HDL, high LDL, high TG) versus 10 out of 27 in the group with normal lipid profiles 
(p<0.001). There was a tendency for the presence of the nephrotic syndrome to have a 
bearing on hyperlipidemia although the number of patients in the study were too small to be 
conclusive.  Given that 60% of the Singaporean lupus patients had renal disease, the 
hyperlipidemia that develops is likely to have a great impact of this cohort of patients. In the 
Bath cohort, only 6% had renal involvement. Nonetheless, the treatment of individuals with 




Active disease can have a bearing on lipid abnormalities via the upregulation of certain 
cytokines such as IL-1,IL-6 and TNF-alpha which in turn suppress lipoprotein lipase and 
cause a Type IV abnormality. This can be seen from studies done on a variety of rheumatic 
diseases. 
 
Active rheumatic disease has been shown to be associated with low HDL levels. As 
mentioned earlier lipid profiles of patients with rheumatoid arthritis, psoriatic arthritis and 
ankylosing spondylitis  when compared to age and gender matched controls show lower 
HDL values.  
 
Svenson et al (60) studied 48 patients with untreated rheumatoid arthritis and 21 with 
seronegative spondyloarthropathy. Compared to healthy controls, these patients with active 
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rheumatic disease had lower levels of VLDL-cholesterol, VLDL-triglyceride, 
HDL-triglyceride and HDL-cholesterol. 
 
Lazarevic et al (61) studied 60 patients with active rheumatoid arthritis, 40 patients with 
psoriatic arthritis, 21 with osteoarthritis and 65 healthy blood donors. Patients with severe 
rheumatoid activity had lower levels of LDL cholesterol and HDL cholesterol. When their 
illness became less active , the serum lipids normalized. This was also the case for psoriatic 
arthritis patients but not for osteoarthritis.  Magaro et al (62) has shown like many others 
that patients with rheumatoid arthritis have lower levels of apoprotein A-I and apoprotein B 
compared with controls. Patients with type IIb hyperlipidemia undoubtedly have a higher 
risk of atherosclerotic clinical events but patients with low levels of HDL and high 
triglyceride levels are also at risk. This is increasingly clear from studies done mainly in 
diabetic patients (63). 
 
The candidate co-authored a study done in Singaporean patients with ankylosing 
spondylitis to determine if active disease was associated with dyslipidemia (64). In these 
patients, there was again a tendency for active disease to be associated with low HDL 
levels. Fasting lipid profiles were obtained from 50 men with ankylosing spondylitis and 50 
age and gender matched controls. Mean age was 31.5 years and none of the patients were on 
corticosteroids. 
 
Presence of risk factors for coronary artery disease, including hypertension, diabetes 
mellitus, familial hyperlipidemia were assessed. Disease activity of ankylosing sponsylitis  
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was assessed using erythrocyte sedimentation rate, C-reactive protein and clinical scoring 
methods namely the Bath Ankylosing Spondylitis Disease Activity, Functional and 
Metrological Indices (BASDAI, BASFI and BASMI). We found that seventy percent had 
abnormal lipid profiles and compared to controls, the patients had lower total cholesterol 
(mean 176.8 mg/dl vs 196 mg/dl, p<0.007) and lower HDL-cholesterol (mean 36.4 mg/dl  
vs 47.6 mg/dl, p <0.001 and higher TC/HDL ratios (5.04 vs 4.32). In this study, the HDL 
was negatively correlated with BASFI (Bath Ankylosing Spondylitis Functional Index) 
with a r of 0.32, p=0.03. There was no correlation with BASDAI and BASMI. 
 
This pattern again suggests that active rheumatic disease is associated with lower HDL 
which supports the hypothesis that there is something which causes it to fall. One 
possibility is the upregulation of cytokines which suppress lipoprotein lipase activity. This 
is difficult to prove conclusively as disease activity is a difficult parameter to measure and 
established scoring methods do not correlate well with serum cytokine levels. This is 
illustrated by another study (65) which the candidate was involved in, looking at the 
relationship between disease activity in ankylosing spondylitis, sex hormone status and 
cytokine levels in relationship to bone mineral density. No correlation was found between 
disease activity as measured by BASDAI, BASFI, BASMI and serum levels of IL-1, IL-6 
and TNF alpha. This could be because tissue levels of cytokines are better measures of 
disease activity than plasma levels but they would be far more difficult to measure and 
more complicated in interpretation. 
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Similiar profiles have been found in active RA,  psoariatic arthritis and ankylosing 
spondylitis.  Jones et al (66) studied 50 psoriatic patients and compared their detailed lipid 
profiles with controls in Bath, UK. The psoriatic patients have significantly lower levels of 
total HDL and HDL3 subfraction. The LDL3 seemed to be elevated in the patients. There 
was also a tendency for higher levels of Lp(a). This combination of low total HDL, HDL3, 
elevated LDL3 and Lp(a) has atherogenic potential (67).  This is similiar to findings in 
rheumatoid arthritis. 
 
Therefore from all these various studies done in rheumatic disease, it appears that compared 
to controls, such patients had lipid abnormalities comprising low HDL, low LDL, low 
apoprotein A1 and apoprotein B. These abnormalities can be brought on when there is 
suppression of lipoprotein lipase activity.  It turns out that one possible mechanism includes 
the suppression of lipoprotein lipase activity by cytokines upregulated in active rheumatic 
disease. It was found as early as 1989 by Fried et al (4) that a single infusion of tumour 
necrosis decreases human adipose tissue lipoprotein lipase mRNA levels, synthesis and 
activity. With the advent of anti-cytokine therapy, there arises the possibility that 
suppression of cytokine activity can favourably alter lipid profiles. This is especially 
relevant in the light of the rapidly growing body of evidence that there may  be some key 
cytokines such as IL 18 involved in atherosclerosis. Wallberg-Jonsson et al (68) studied the 
relationship between lipoprotein lipase activity and mass, blood lipid profiles and 
inflammatory variables in rheumatoid arthritis patients. Lipoprotein lipase activity was 
lower  in the patients versus controls. This was inversely related to inflammatory markers 
such as C reactive protein and IL6 but not for lipid levels. This could be because of the 
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small numbers as there were only 17 patients versus 16 controls.  Ilowite et al (69) 
identified dynamic changes in lipid profiles in a set of paediatric SLE patients studied 
longitudinally. The mean HDL-cholesterol and apo-AI was markedly lower in untreated 
and clinically active SLE patients compared with controls. When the illness was treated and 
SLE became inactive, HDL-cholesterol and apo-AI rose. 
 
Other possible mechanisms include the effect of anti-lipoprotein antibodies and the role of 
acute phase reactants such as serum amyloid A protein in modifying HDL metabolism. 
Lazarevic et al (57) found that anti-lipoprotein antibodies against VLDL and LDL were 
present in 26 of 69 (38%) of patients with active rheumatoid arthritis but not in patients 
with osteoarthritis, psoriatic arthritis or healthy blood donors. Patients with these antibodies 
had lower cholesterol levels in all subfractions and elevated serum triglycerides. 
 
Another mechanism could be mediated via acute phase reactants such as serum amyloid A 
protein. Kumon et al (70) showed that in patients with rheumatic disease, total HDL 
cholesterol, apoprotein A-I and apoprotein A-II were lower than in normal subjects and 
were inversely correlated with plasma concentrations of serum amyloid A protein (SAA). 
SAA displaces apo A-I and apo A-II which results in increased catabolism of HDL. 
 
Measurement of lupus activity is not easy. In the Singaporean study we used the LACC 
(Lupus Activity Criteria Count) which is an earlier tool and we found a tendency for active 
SLE to be associated with a low HDL. This pattern was also seen in the cohort of paediatric 
lupus patients studied by Ilowite et al and is consistent with the other studies done on 
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rheumatoid arthritis and psoriatic arthritis. In 1990 when the Singapore study was done, 
newer indices of lupus activity were not yet routinely in use. 
 
In the Bath cohort, we used BILAG (British Isles Lupus Activity Group) score, which is a 
more accurate measure of lupus activity. This index is also sensitive to change. We directly 
measured cytokine profiles namely, IL-1, soluble IL-2 receptor and TNF-alpha. Lipid 
metabolism was studied at length via the subfractionation of cholesterol and also 
measurement of hepatic lipase and lipoprotein lipase activity by a post-heparin challenge. 
 
In the Bath cross-sectional study we found that SLE patients have low HDL2, low 
apoprotein I when compared to age and gender matched controls from the same region in 
the UK.  This is in stark contrast to the Singaporean cohort who have elevated TC and LDL, 
high TG and low total HDL. The differences could possibly  be attributed to the differences 
in the severity of lupus particularly the presence of renal disease and the nephrotic 
syndrome , degree of lupus activity and the usage of corticosteroids. 
 
In this cohort, we unfortunately did not have complete data collection in all respects except 
for nine patients. These patients never had renal disease and were not on corticosteroids. 
They had serial measurements of a full cytokine profiles (soluble IL-2 receptor, TNF-alpha, 
IL6, and IL 1-beta), and measurements of serum total cholesterol, LDL-chol, total 
HDL-chol, HDL 2 and HDL 3 subfractions, TG, apoprotein A1 and apoprotein B. 
 
In these patients studied serially, sIL2R and apoprotein AI generally correlated and this 
could be indirect evidence that our hypothesis holds true. Among the various serum 
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cytokines, the only one that correlated with the BILAG was sIL2R. In  the patients who had 
increase in sIL2R, the activity status was also higher when assessed by BILAG and the 
apoprotein AI was lower.  
 
It turns out that of the seven patients who had a fall in sIL-2R levels, all had a concomitant 
rise in apoprotein A1. This seems to support the hypothesis that lupus activity causes a fall 
in HDL through suppression of lipoprotein lipase activity. However, the number of study 
subjects was small and this finding has to be confirmed by larger studies. Also in this study, 
the BILAG, a clinical scoring method did not correlate well with dynamic changes in serum 
cytokines. 
 
Assessment of lupus activity, measuring upregulation of cytokines and measurement of 
lipoprotein lipase directly are extremely difficult and probably accounts for the failure of 
our study to establish a firm link between these disease mechanisms. We did find however 
that in this cohort of SLE patients with relatively low frequency of renal disease and 
corticosteroid usage, lipid profiles suggest suppression of liprotein lipase activity. This 
supports the hypothesis that a Type IV dyslipidemia is found in active rheumatic disease. 
We were able to show this probably because this particular cohort of patients had a low 
frequency of renal disease and steroid use which would have been major confounding 
factors. We were however unable to show differences in serum levels of apoproteins A, B. 
Nonetheless our study suggests that active disease itself is a contributor to the problem 
through a mechanism mediated through the upregulation of cytokines in active rheumatic 
disease.  This may present opportunities for novel  therapeutic interventions. 
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 The role of active SLE causing changes in cytokine profiles which in turn lead to lipid 
abnormalities is further supported by research done on other cohorts. Svenungsson et al 
(71) further documents this phenomenon in a study involving two hundred and eight SLE 
patients. Disease activity was assessed using SLAM and fasting blood was analysed for 
lipid profiles and serum TNF alpha, soluble TNF Type 1 (sTNFR1) and Type 2 (sTNFR2) 
receptors. Serum TG was found to be associated with SLAM score (r=0.48, p<0.0001), 
TNF alpha (r=0.29, p=0.0001), sTNFR1 (r=0.38, p<0.0001), sTNFR2 (r=0.40, p<0.0001). 
HDL levels on the other hand were negatively associated with SLAM score (r= -0.27, 
p=0.0003), TNF alpha (r= -0.15, p=0.04) and sTNFR2 (r= -0.19, p=0.01). In multiple 
logistic regression models, TNF alpha and serum TG were independent determinants of 
active disease as assessed by SLAM (p=0.003 for both). Therefore active SLE was shown 
to increase TNF alpha and its soluble receptors which then caused a rise in TG and a fall in 
HDL This study then strongly supports the explanation for low HDL in the Bath cohort and 
also the Singapore cohort as being related to active SLE causing upregulation of cytokines 






 What could be the clinical consequences of hyperlipidemia in SLE? 
 
Hyperlipidemia carries with it several clinical consequences many of which are related to 
thrombotic events such as myocardial infarction and cerebrovascular thrombosis (72). 
Hence it would be interesting to know the extent to which this is a problem for SLE patients 
with persistent hyperlipidemia. In the previous section, it was pointed out that SLE patients 
as well as patients with other rheumatic diseases such as rheumatoid arthritis have been 
shown to have excess mortality from ischemic events. 
 
The candidate performed a follow up study of the initial cohort of 100 Singaporean SLE 
patients after a period of five years to determine their outcomes. This study demonstrated 
that there was a significant number who developed complications from treatment including 
infections, cataracts and avascular necrosis. A number of patients had new manifestations 
of lupus while on follow up. Mortality was associated with a young age of onset of lupus 
and the presence of severe lupus nephritis. However, there were no new atherosclerotic 
events during these five years. Two of the patients already had a history of thrombotic 
events probably due to hyperlipidemia when they were first recruited in 1990 but they were 
no other new patients similiarly affected. There were 13 patients who were lost to follow up 
and it is not known if any of them had atherosclerotic complications. It must be 
remembered that this was a young cohort of patients with a mean age of 32. It is likely that 
a five year follow up period is too short to be able to detect signficant mortality and  




RATIONALE FOR TREATMENT 
 
As has been discussed, rheumatic diseases carry an increased risk of morbidity and 
mortality from premature atherosclerosis. Rheumatoid arthritis is associated with increased 
mortality. Prior et al (73) studied 489 consecutive patients with classical rheumatoid 
arthritis followed up for a mean of 11.2 years and found a three fold increase in overall 
mortality compared with age and sex-specific rates in the general population. 
Cardiovascular deaths were 2.5 times higher than expected. Rasker and Cosh (74) followed 
up a cohort of 100 RA patients for 18 years. Of the 43 who died, 16 were related to RA and 
27 were unrelated. In the latter group, 14 were cardiac deaths and 8 were cerebrovascular 
events. 
 
In patients on long term corticosteroid therapy, the main abnormalities are in the LDL 
subfraction. There have been many studies which clearly show the relationship between 
hypercholesterolemia and the risk of coronary artery disease. The Framingham study (75) 
showed that this risk is positively associated with levels of LDL cholesterol and inversely 
associated with HDL levels. This is particularly interesting as active rheumatic diseases 




There is good evidence that the treatment of lipid abnormalities result in improved 
outcomes. The US Lipid Research Clinics Coronary Primary Prevention Trial (76) 
randomized 3,806 men in a double blind study lasting 7 to 10 years. The treatment group 
received cholestyramine and showed a reduction in the total and LDL cholesterol levels. 
This was associated with a reduction in primary end points of deaths related to coronary 
artery disease and non-fatal myocardial infarctions. There was also a reduction in angina, 
positive exercise ECG and requirement for coronary bypass surgery. The Helsinki Heart 
Study (77) showed that lowering of serum triglyceride and raising of HDL levels led to a 
reduction in fatal and non-fatal myocardial infarction.  
 
There have also been studies which use angiographic evidence of regression of coronary 
atherosclerosis as endpoints. The Cholesterol-Lowering Atherosclerosis Study (78) showed 
that colestipol combined with niacin can lead to regression in coronary atherosclerosis as 
assessed by coronary angiography. 
 
Besides causing clinical events related to vascular thrombosis, dyslipidemia can accelerate 
the progression of renal disease. Type IIb hyperlipidemia is well known to be associated 
with the presence of a nephrotic syndrome which is common in lupus nephritis. In the past, 
it was thought that hyperlipidemia from the nephrotic syndrome did not require 
pharmacological therapy as it will resolve when the nephrotic syndrome improves. 
However, there are many patients in whom there is persistent renal involvement and hence 
persistent hyperlipidemia and they too then become at risk for atherosclerotic 
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complications. Therefore, SLE patients who are persistently nephrotic need to be assessed 
for hyperlipidemia and they should be treated if appropriate.  
 
Gheith et al (79) randomized 43 idiopathic nephrotic syndrome patients into a treatment 
group with fluvastatin and a control group. In the treated group there was a reduction in TC, 
LDL and TG but also improvement in proteinuria, creatinine clearance and serum albumin. 
Renal biopsy revealed reduction in interstitial fibrosis and renal fat deposits in the treated 
group. The Simvastatin in Nephrotic Syndrome Study Group (80) conducted a two year, 
prospective double blind trail involving 56 patients with primary glomerulonephritis and 
nephrotic syndrome. The patients were randomized into a treatment group with simvastatin 
and a placebo group. Achieving target levels of LDL HDl and TC were possible and safe.  
 
The role of active disease and pro-inflammatory cytokines in the development of 
hyperlipidemia and atherosclerosis is increasingly recognized. Mizia-Stec et al (81) found 
that coronary artery disease is associated with increased serum levels of TNF alpha. TNF 
alpha is negatively associated with HDL and positively associated with TG. However, in 
the obese Zucker rat, anti-TNF treatment did not reverse any of the lipid abnormalities (82). 
However,  in patients with active RA who were treated with adalimumab, an anti-TNF 
therapy, Popa et al (83) showed that there was an increase in HDL and reduction in CRP 
and IL 6 levels after two weeks. Whether this translates into a lower cardiovascular risk 
would require further study. Therefore it seems attractive to treat the inflammatory process 
with cytokine therapy to reduce the risk of atherosclerotic events. However the best 
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Risk factors for hyperlipidemia and premature atherosclerosis have to be assessed for the 
individual patient. Some of these factors are amenable to modification. Smoking cessation, 
a sensible exercise program and weight control are important. Diabetes mellitus, steroid 
induced or otherwise has to be adequately treated.   The role of hyperhomocyteinemia and 
folate supplementation should be considered. 
 
The level of serum lipids to be attained would be based on studies in the indigenous 
population. An example is the US National Cholesterol Education Programme guidelines 
(84).  The Ministry of Health, Singapore together with National Medical Research Council, 
Singapore Cardiac Society and National Committee on Cardiac Care published Clinical 
Practice Guidelines in July 2001 concerning Lipids (85). Lipid goal levels and levels for 
initiating drug therapy depends on the number of risk factors present and whether there is 
coronary heart disease (CHD) or CHD risk equivalents.  This is summarised in Table 9. 
CHD equivalents are cerebrovascular or peripheral artery disease, diabetes mellitus. Risk 
factors are cigarette smoking, hypertension greater or equal to 140/90 or on 
anti-hypertensive medication, family history of premature CHD (CHD in male first degree 
relative younger or at age 55; or in female first degree relative younger or at age 65), age 45 










Table 9 Lipid Goal levels and level for starting drug therapy  
Lipid levels in mg/dl, level for starting drugs in brackets 
 
  CHD or CHD  > or =2 Risk   0-1 Risk  
                       Equivalents                  Factors   Factors 
TC  >160 (200)  >200 (240)  >240 (280) 
LDL   >100 (130)  >130 (160)  >160 (190)  
TG  >200 (250)  >200 (400)  >200 (400) 








 Dietary intervention plays a major role as a baseline measure in the treatment of 
hyperlipidemia. In mild cases, this may be all that is necessary to achieve the therapeutic 
target. An ideal weight should be maintained with a Body mass index between 18.5 and 23 
kg/sq metres. Out of total calories per day, saturated fat should make up no more than 7%, 
total fat 25-30%, polyunsaturated fat up to 10%, monounsaturated fat up to 10%, 
carobohydrates as mainly complex carbohydrates 60%, protein 15%, fibre 10g/1000kcal 
per day and cholesterol <200 mg a day. However a study of dietary intervention in SLE 
patients (86) showed that after 6 months there was a reduction in only one parameter, 
namely total cholesterol. Therefore it is important to institute drug therapy if the therapeutic 
targets cannot be achieved by diet alone. 
 
Cigarette smoking should be stopped. Aerobic exercise three or four times a week is 
recommended with each session lasting 30-40 minutes. Beneficial exercises include brisk 
walking, jogging, swimming and cycling. For lupus patients, sun protection must be 
remembered and if there is concomitant osteoporosis, weight bearing exercise is important 
as well. Alcohol intake should be restricted in patients with hypertriglyceridemia.  
 
In some patients, dietary measures alone are inadequate and pharmacological agents have 
to be used. These include statins, fibrates, niacin, cholestyramine and probucol. Efficacy of 
these agents have been well proven, in particular statins such as simvastatin, pravastatin, 
atovarstatin and rosuvastatin. Their role in primary as well as secondary prevention of 
coronary events and stroke have been demonstrated in large randomised controlled trials 
 95
(87-91). The drug of choice depends on the lipid profile. In patients with high TG and low 
HDL, a fibrate would be a better initial choice whereas high LDL responds well to statins. 
In selected patients, combination therapy may be indicated. 
 
With regards to factors related to SLE, the rheumatologist should control active disease, 
minimise the steroid dose where possible and consider the use of steroid sparing drugs 
especially antimalarial agents which seem to have a beneficial effect on lipid profiles in 
these patients. In future it may be possible to use anti-cytokine therapy in improving lipid 
profiles through regulation of cytokines involved in lipid metabolism. If there were certain 
key cytokines involved in atherosclerosis, then blocking these cytokines should have 
greater efficacy with fewer side effects and would be an advance in the treatment of 
atherosclerosis. The same concept has now been proven to be true for anti-TNF therapy in 
the treatment of rheumatoid arthritis.  
 
THE ROLE OF HYDROXYCHLOROQUINE 
 
Hydroxychloroquine is often used in the treatment of mild SLE and RA. Besides its 
immune-modulating effects, it has a protective role with regards to hyperlipidemia 
induced by corticosteroids. Hodis et al (92) performed a case-control study comparing 
patients with SLE who were on hydroxychloroquine versus those who were not. The 
treatment group had 35-45% lower levels of total triglyceride, VLDL-triglyceride, 
LDL-triglyceride, HDL-triglyceride, VLDL-cholesterol and apoprotein CIII. Wallace et al 
(93) studied 155 women with RA or SLE and divided them into four groups, namely 
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hydroxychloroquine without steroids, steroids without hydroxychloroquine, both steroids 
and hydroxychloroquine and neither. He found that hydroxychloroquine was strongly 
associated with low serum levels of cholesterol, triglycerides and LDL-cholesterol 
regardless of concomitant steroid use. Petri et al (94) performed a cohort longitudinal study 
involving 264 patients with SLE. In a regression model for steroid use, a change in 
prednisone dose of 10 mg was associated with a change in cholesterol level of 7.5 +/- 1.46 
mg% and a weight gain of 5.5 +/- 1.23 pounds. On the other hand, hydroxychloroquine at 
200 mg or 400 mg per day were both associated with lower serum cholesterol. Tam et al 
(95) also found that  TC, VLDL, LDL were significantly lower in patients taking 








Current data therefore suggests that there is a tendency for premature death in  patients with 
rheumatic diseases. One significant contributor is the presence of cardiovascular or 
cerebrovascular disease. As our ability to manage such patients improves with time and 
new knowledge, survival of patients can now be significantly prolonged. This makes it 
important for rheumatologists to be aware of potential problems related to premature 
atherosclerosis in their patients. 
 
The prevalence of premature atherosclerosis among SLE patients is increasingly 
recognised. In three large SLE cohorts namely the Toronto cohort (96),  the Baltimore 
cohort (97) and the Pittsburgh cohort (98),  factors associated with clinical coronary artery 
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disease were identified. Older age at onset of diagnosis and hyperlipidemia were found to 
be important in all three cohorts. Longer duration of steroid therapy and hypertension were 
present in two of the three. Other risk factors were related to active SLE such as pericarditis 
and others were non lupus related such as postmenopausal status, diabetes mellitus, 
antihypertensive treatment and congestive heart failure. 
 
In this thesis, SLE patients from Bath and Singapore were studied.  The Bath cohort is a 
more typical Western lupus cohort with generally milder disease, older age of onset and 
less usage of steroids. The Singapore cohort has more severe lupus disease, younger age of 
onset and generally need higher doses of steroids. Despite the use of steroid sparing agents, 
such patients often do develop complications of steroid therapy. Therefore, it is all the more 
important for the rheumatologist managing such patients to be extra vigilant with regards to 
monitoring and treating such complications early.  In the Toronto study  it was found that 
there was variability in the management of risk factors for coronary artery disease among 
rheumatologists. They did consistently well in trying to minimise steroid doses used,  
control disease activity and manage hypertension. There was less consistency in 
approaching modification of  hyperlipidemia, obesity and smoking.  In the Hopkins cohort 
(69),  there was poor patient awareness that they were at increased risk of coronary artery 
disease and extremely low use of preventive practices. 
 
Therefore, hyperlipidemia should always be considered when managing a patient with SLE 
(99). Early detection and treatment will lead to improved outcomes and lower the risk of 


















 This thesis has explored the issue of hyperlipidemia in patients with systemic lupus 
erythematosus  and the following conclusions can be drawn: 
 
1) Hyperlipidemia is a common phenomenon in systemic lupus erythematosus in 
Singapore, particularly in those who have moderate to severe disease. The pattern of 
abnormalities are a high TC, LDL, TG and a low HDL. In the Bath SLE cohort, the only 
abnormality seen is low HDL. 
 
2) Hyperlipidemia in SLE is associated with the presence of nephrotic syndrome the use of 
systemic corticosteroids and  possibly active lupus disease.  
 
3)   The clinical consequences of persistent hyperlipidemia in SLE has to be better 
       documented but it would seem sensible to treat this to prevent premature 










1) Belch JJF, Ansell D, Madhok R, O'Dowd A, Sturrock RD: Effects of altering dietary 
essential fatty acids on requirements for non-steroidal anti-inflammatory drugs in patients 
with rheumatoid arthritis: a double blind placebo controlled study. Ann Rheum Dis 1988; 
47:96-104. 
 
2) Bittiner SB, Tucker WFG, Cartwright I, Bleehen SS: A double blind, randomised, 
  placebo-controlled trial of fish oil in psoriasis. Lancet 1988; 1:378-80. 
 
3) Leventhal LJ, Boyce EG, Zurier RB: Treatment of rheumatoid arthritis with 
      gammalinolenic acid. Ann Intern Med 1993; 119:867-73. 
 
4) Fried SK, Zechner R. Cachetin/tumour necrosis factor decreases human adipose 
tissue lipoprotein lipase mRNA levels, synthesis and activity. Journal of Lipid Research 
1989; 30: 1917-23. 
 
5)  Yamashita H, Shimada K, Seki E, Mokuno H, Daida H: Concentrations of interleukins, 




6) Van der Meer IM, De Maat MP, Hak AE, Kiliaan AJ, Del Sol AI, Van der Kuip DA et al: 
C-reactive protein predicts progression of atherosclerosis measured at various sites in the 
arterial tree: the rotterdam study. Stroke 2002; 33: 2750-5. 
 
7)  Devaraj S, Xu DY, Jialal I: C-reactive protein increases plasminogen activator inhibitor 
–I expression and activity in human aortic endothelial cells: implications for the metabolic 
syndrome and atherothrombosis. Circulation 2003; 107: 398-404. 
 
 8) Elhage R, Jawien J, Rudling M, Ljunggren HG, Takeda K, Akira S: Reduced 
atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardiovasc Res 
2003; 59 (1): 234-40. 
 
9) Mallat Z, Henry P, Fressonnet R, Alounai S, Scoazec A, Beaufils P et al: Increased 
plasma concentrations of interleukin-18 in acute coronary syndromes. Heart 2002; 
88(5):467-9. 
 
10) Yamaoka-Tojo M, Tojo T, Masuda T, Machida Y, Kitano Y, Kurosawa T et al: 
C-reactive protein-induced production of interleukin-18 in human endothelial cells: a 
mechanism of orchestrating cytokine cascade in acute coronary syndrome. Heart Vessels 
2003; 18: 183-7 
 
 102
11) Esposito K, Pontillo A, Ciotola M, Di Palo C, Nicoletti G, Giugliano D: Weight loss 
reduces interleukin-18 levels in obese women. J Clin Endocrinol Metab 2002; 87 (8): 
3864-6. 
 
12) Van Wissen S, Trip MD, Smilde TJ, deGraaf J, Stalenhoef AF, Kastelein JJ. 
Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with 
aggressive or conventional statin therapy. Atherosclerosis 2002; 165: 361-6. 
 
13) Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, duBerger R et al: 
Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in 
SLE. Arthritis Rheum 2001; 44: 2331-7. 
 
14) Oxford Textbook of Rheumatology Editors: Isenberg, Maddison, Woo and Glass 
Systemic lupus erythematosus. Isenberg DA, Horsfall AC. Pp 1145-80. 2nd edition Oxford 
Press. 
 
15) Tan EM et al. The 1982 revised criteria for the classification of systemic lupus 
erythematosus. Arthritis and Rheum 1982; 25: 1271-7. 
 
16) Ettinger WH, Goldberg AP, Applebaum-Bowden D, Hazzard WR: 
  Dyslipoproteinemia in SLE - effect of corticosteroids. Am J Med 1987; 83:503-8. 
 
17) Kabakov AE, Tertov VV, Saenko VA, Poverenny AM, Orekhov AN:The atherogenic 
 103
 effect of lupus sera: SLE-derived immune complexes stimulate the accumulation of 
 cholesterol in cultured smooth muscle cells from human aorta. Clin Immunology and 
 Immunopathology 1992; 63(3):214-20. 
 
18)  Takegoshi T, Haba T, Hirai J, Saga T, Kitoh C, Mabuchi H: A case of 
 hyperLp(a)aemia associated with SLE, suffering from myocardial infarction and 
 cerebral infarction. Jap J Med 1990; 29:77-84. 
 
19)  Rantapaa-Dahlqvist S, Wallberg-Jonsson S, Dahlen G: Lipoprotein (a), lipids and 
 liporoteins in patients with rheumatoid arthritis. Ann Rheum Dis 1991; 50:366-8. 
 
20)  Aoki K, Kawai S: Glucocorticoid therapy decreases serum lipoprotein (a) 
 concentration in rheumatic diseases. Internal Medicine 1993; 32:382-6. 
 
21)  MacGregor AJ, Dhillon VB, Binder A et al: Fasting lipids and anticardiolipin 
 antibodies as risk factors for vascular disease in SLE. Ann Rheum Dis 1991; 51:152- 
55. 
 
22)  Lahita RG, Rivkin E, Cavanagh I, Romano P: Low levels of total cholesterol, HDL 
 and apolipoprotein A-I in association with anticardiolipin antibodies in patients with 
 SLE. Arthritis Rheum 1993; 36:1566-74. 
 
 104
23) Thumboo J, Uramoto K, O’Fallon WM, Fong KY, Boey ML, Feng PH et al: A 
comparative study of the clinical manifestations of SLE in Caucasians in Rochester, 
Minnesota and Chinese in Singapore from 1980-1992. Arthritis Rheum 2001; 45 (6): 
494-500. 
 
24) Mok CC, Lau CS: Lupus in Hong Kong Chinese. Lupus 2003; 12 (9): 717-22 
 
25)  Leong KH, Koh ET, Feng PH, Boey ML: Lipid profiles in patients with SLE. 
 J Rheumatol 1994; 21:1264-7. 
 
26)  Urowitz MB, Gladman DD, Tozman ECS et al:  The lupus activity criteria count      
(LACC).  J Rheumatol 1984; 11: 783-7. 
 
27)  KH Leong, CA Stirling, J Lloyd, Reckless J, Maddison PJ, McHugh NJ. SLE patients 
 have abnormal lipid profiles compared to age and gender matched controls. Lupus 
 1995; 4: 149 (abstract). 
 
28)  Ettinger WH, Hazzard WR. Elevated apolipoprotein B levels in corticosteroid treated 
patients with SLE. J Clin Endocrin and Metab 1988; 67: 425-8. 
 
29)  Grundy SM. Management of hyperlipidemia of kidney disease. Kidney Int 1990; 
 37: 847-53. 
 
 105
30) Gunnarsson I, Sundelin B, Heimburger M, Forslid J,van Vollenhoven B, Lundberg I et 
al. Repeated renal biopsies in proliferative lupus nephritis – predictive role of serum 
C1q and albuminuria. J Rheumatol 2002; 29: 693-9. 
 
31)  Bajaj S, Albert L, Gladman DD, Urowitz MB, Hallett DC, Ritchie S. Serial renal 
biopsy in SLE. J Rheumatol 2000; 27: 2822-6.  
 
32) Hay EM, Bacon PA, Gordon C et al: The BILAG index: a reliable and valid instrument 
for measuring clinical disease activity in systemic lupus erythematosus. Quarterly J 
Med 1993; 86: 447-58 
 
33) Liang MH, Fortin PR, Isenberg DA et al: Quantitative clinical assessment of disease 
activity in SLE – progress report and research agenda. Rheumatol Int 1991; 11: 133-6. 
 
34) Bombardier C, Gladman DD, Urowitz MB et al: Derivation of the SLEDAI – a disease 
activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis 
Rheum 1992; 35: 630-40. 
 
35)   Leong KH, Koh ET, Feng PH, Boey ML. The clinical outcome of 100 SLE patients 
 after five years of follow up. APLAR J of Rheumatol 1997; 1: 23-6. 
 
36)  Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic 
lupus erythematosus. Results from a single centre. J Rheumatol 1995; 22: 1259-64. 
 106
 37)  Urowitz MB, Bookman AAM, Koehler BE et al: The bimodal mortality pattern of 
      SLE. Am J Med 1976; 60:221-5. 
 
38)  Petri M, Perez-Gutthann S, Spence D, Hochberg MC: Risk factors for coronary artery 
       disease in patients with SLE. Am J Med 1992;  93(5):513-9. 
 
39)  Bulkley BH, Roberts WC: The heart in SLE and the changes induced in it by 
      corticosteroid therapy - a study of 36 necropsy patients. Am J Med 1975; 58:243-64. 
 
40) Attman PO, Alaupovic P, Samuelsson O: Lipoprotein abnormalities as a risk factor for 
progressive non diabetic renal disease. Kidney Int 1999, 71: S 14-17. 
 
41) Kallen RJ, Brynes RK, Aronson AJ et al : Premature atherosclerosis in a 5 year old with 
corticosteroid-refractory nephrotic syndrome. Am J Dis Child 1977, 131: 976-80. 
 
42) Roman MJ, Shanker BA, Davis A et al : Prevalence and correlates of accelerated 
atherosclerosis in systemic lupus erythematosus. New Engl J  Med 2003, 349: 2399-406. 
 
43) CE Tan, ES Tai, CS Tan et al: APOE polymorphism and lipid profiles in three ethnic 
groups in the Singapore population. Atheroslerosis 2003, 170: 253-60. 
 
 107
44) Kawakami M, Murase T, Ogawa H et al: Human recombinant TNF suppresses 
lipoprotein lipase activity and stimulates lipolysis in 3T3-L1 cells.  J Biochem (Tokyo) 
1987, 101: 331-8. 
 
45) Feingold KR, Grunfeld C: Role of cytokines in inducing hyperlipidemia. Diabetes 
1992, 41: S 97-101. 
 
46) Tengku-Muhammad TS, Cryer A, Ramji DP: Synergism between interferon gamma 
and tumour necrosis factor alpha in the regulation of lipoprotein lipase in the macrophage 
J774.2 cell line. Cytokine 1998, 10: 38-48. 
 
47) Levy E, Gurbindo C, Lacaille F et al: Circulating tumour necrosis factor –alpha levels 
and lipid abnormalities in patients with cystic fibrosis. Pediatr Res 1993, 34: 162-6. 
 
48) Sella EM, Sato EI, Leite WA et al: Myocardial perfusion scintigraphy and coronary 
disease risk factors in systemic lupus erythematosus. Ann Rheum Dis 2003, 62: 1066-70. 
 
49) Oxford Textbook of Rheumatology Editors: Isenberg, Maddison, Woo and Glass 
Hyperlipidemias. Leong KH, Reckless J, McHugh NJ. Pp 1478-88 2nd Ed, Oxford Press. 
 
50) Zimmerman J, Fainaru M, Eisenberg S. The effects of prednisone therapy on plasma 
lipoproteins and apolipoproteins. A prospective study. Metabolism 1984; 33: 521-6. 
 
 108
51) Becker DM, Chamberlain B, Swank R et al: Relationship between corticosteroid 
exposure and plasma lipid levels in heart transplant patients. Am J Med 1988, 85: 632-8. 
 
52) Formiga F, Meco JF, Pinto X: Lipid and lipoprotein levels in premenopausal systemic 
lupus erythematosus patients. Lupus 2001, 10: 359-63. 
 
53) Doria A, Schonfeld Y, Wu R et al: Risk factors for subclinical atherosclerosis in a 
prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2003, 
62: 1071-7. 
 
54)  Petri M, Lakatta C, Magder L, Goldman D: Effect of prednisone and 
 hydroxychloroquine on coronary artery disease risk factors in SLE: a longitudinal 
data analysis. Am J Med 1994; 96:254-9. 
 
55) Martinez-Berriotxoa A, Ruiz-Irastorza G, Egurbide Arberas MV et al: Plasma 
homocysteine levels in systemic lupus erythematosus. Med Clin 2003, 120: 681-5. 
  
56)  Wheeler DC, Nair DR, Persaud JW et al: Effects of dietary fatty acids in an animal 
 model of focal glomerulosclerosis. Kidney Int 1991; 39:930-7. 
 
57)  Winyard PG, Tatzber F, Esterbauer H, Kus ML, Blake DR, Morris CJ. Presence of 
foam cells containing oxidised LDL in the synovial membrane from patients with 
rheumatoid arthritis. Ann Rheum Dis 1993; 52: 677-80. 
 109
 58) Luzar B, Ferluga D: Role of lipids in the progression of renal disease in systemic lupus 
erythematosus patients. Wien Klin Wochenschr 2000, 112: 716-21. 
 
59) Font J, Ramos-Casals M, Cervera R et al: cardiovascular risk factors and the long term 
outcome of lupus nephritis. QJM 2001, 94: 19-26. 
 
60)   Svenson KLG, Lithell H, Hallgren R, Vessby B: Serum lipoprotein in active 
     rheumatoid arthritis and other chronic inflammatory arthritides. Arch Intern Med 
     1987; 147:1917-20. 
 
61)  Lazarevic MB, Vitic J, Myones BL et al: Anti-lipoprotein antibodies in rheumatoid 
 arthritis. Semin Arthritis Rheum 1993; 22:385-91. 
 
62)  Magaro M, Altomonte L, Zoli A, Mirone L, Ruffini MP: Serum lipid pattern and 
 apolipoprotein A-I and B100 in active rheumatoid arthritis. Zeitschrift fur 
 Rheumatologie 1991; 50:168-70. 
 
63)  Krentz AJ Lipoprotein abnormalities and their consequences for patients with type 2 
diabetes. Diabetes Obes Metab 2003; suppl 1: S19-27. 
 
64)  Leong KH, Koh WH, Seah R, Lim SH, Fong KY. Dyslipidemia in patients with 
 ankylosing spondylitis. ankylosing spondylitis. Proceedings of ILAR Scientific 
 110
 Meeting 1997; pp74. 
 
65)  Koh WH, Aziz NK, Chan L, Seah R, Tin SK, Leong KH, Fong KY. Bone mineral 
 density of oriental males with ankylosing spondylitis. The relationship of disease 
 severity, sex hormone status and cytokines. Proceedings of ILAR Scientific Meeting 
1997; pp74. 
 
66)  Jones SM, Lloyd J, Barnes J, Stirling CA, Harris CPD, Reckless JPD, McHugh NJ. 
 Lipoproteins and their subfractions in psoariatic arthritis. Arthritis and Rheumatism 
 1994; 37: S206. 
 
67)  Maher VMG, Brown BG. Lipoprotein (a) and coronary heart disease. Curr Opin in 
Lipidology 1995; 6: 229-35. 
 
68) Wallberg-Jonsson S, Dahlen G, Johnson O et al: Lipoprotein lipase in relation to 
inflammatory activity in rheumatoid arthritis. J Intern Med 1996, 240:373-80. 
 
69) Ilowite NT, Samuel P, Ginzler E, Jacobson MS: Dyslipoproteinemia in paediatric 
systemic lupus erythematosus. Arthritis Rheum 1988; 31: 859-63. 
 
70)  Kumon Y, Suchiro T, Ikeda Y, Yoshida K, Hashimoto K, Ohno F: Influence of serum 
 amyloid A protein on HDL in chronic inflammatory disease. Clin Biochem 1993; 
 26:505-11. 
 111
 71) Svenungsson E, Gunnarsson I, Fei GZ et al: Elevated triglycerides and low levels of 
high density lipoprotein as markers of disease activity in association with up-regulation of 
the tumour necrosis factor  alpha/TNF receptor system in SLE.   
 
72)  Neaton JD, Blackburn H, Jacobs D et al. Serum cholesterol level and mortality 
 findings for men screened in the multiple risk intervention trial. Archives of Int Med 
 1992; 152: 1490-500. 
 
73)  Prior P, Symmons DPM, Scott DL, Brown R, Hawkins CF: Cause of death in 
       rheumatoid arthritis. Br J Rheumatol 1984; 23:92-9. 
 
74)  Rasker JJ, Cosh JA: Cause and age of death in a prospective study of 100 patients 
       with rheumatoid arthritis. Ann Rheum Dis 1981; 40:115-20. 
 
75) Castelli WP, Garrison RJ, Wilson PWF et al: Incidence of coronary heart disease and 
 lipoprotein cholesterol levels.The Framingham Study. JAMA 1986; 256:2835. 
 
76)  Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary 
 Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 




 77)  Frick MH, Elo O, Haapa K et al: Helsinki Heart Study: primary prevention trial with 
 gemfibrozil in middle-aged men with dyslipidaemia. N Engl J Med 1987; 317:1237- 
 45. 
 
78)  Blankenhorn DH, Nessim SA, Johnson RL et al: Beneficial effects of combined 
 colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass 
 grafts. JAMA 1987; 257:3233. 
 
79) Gheith OA, Sobh MA, Mohamed Kel-S et al: Impact of treatment of dyslipidemia on 
renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. 
Nephron 2002, 91:612-9. 
 
80) Olbricht CJ, Wanner C, Thiery J et al: Simvastatin in nephrotic syndrome. Kidney Int 
1999, 71: S113-6. 
 
81) Mizia-Stec K, Zahorska-Markiewicz B, Mandecki T et al: Hyperlipidemias and serum 
cytokines in patients with coronary artery disease. Acta Cardiol 2003, 58: 9-15. 
 
82) Lopez-Soriano J, Lopez-Soriano FJ, Bagby GJ et al: Anti-TNF treatment does not 




83) Popa C, Netea MG, Radstake T et al: Influence of anti-TNF treatment on the 
cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis 
2004, July (epub) 
 
84)  The Expert Panel: Report of the National Cholesterol Education Program Expert 
 Panel on detection, evaluation and treatment of high blood cholesterol in adults. Arch 
 Intern  Med 1988; 143:36-69. 
 
85)   Clinical Practice Guidelines on Lipids. Ministry of Health, Singapore Nov 2001. 
 
86) Hearth-Holmes M, Baethge BA, Broadwell L et al: Dietary treatment of hyperlipidemia 
in patients with SLE. J Rheumatol 1995, 22: 450-4. 
 
87)  Scandinavian Simvastatin Survival Study Group (4S). Randomised trial of 
 cholesterol lowering in 4444 patients coronary heart disease: results of the 4S study. 
 Lancet 1994; 344: 1383-9. 
 
88)  West of Scotland Coronary Prevention Study Group. Influence of pravastatin and 






 89)  The Long term Intervention with Pravastatin in Ischemic Disease (LIPID) Study 
 Group. Prevention of cardiovascular events and deaths with pravastatin in patients 
 with coronary heart disease and a broad range of initial cholesterol levels. N Engl J 
 Med 1998; 359: 1349-57. 
 
90) Colhoun HM, Betteridge DJ, Durrington PN et al: Primary prevention of cardiovascular 
disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes 
Study (CARDS): multicentre randomised placebo-controlled trial.  
Lancet 2004, 364: 685-96. 
 
91) Schwartz GG, Bolognese MA, Tremblay BP et al:  Efficacy and safety of rosuvastatin 
and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart 
disease: a randomised controlled trial. Am Heart J 2004, 148: e pub 
 
92) Hodis HN, Quismorio FP, Wickham E, Blankenhorn DH: The lipid, lipoprotein and 
apolipoprotein effects of hydroxychloroquine in patients with SLE. J Rheumatol 1993; 
 20:661-5. 
 
93) Wallace DJ, Metzger AL, Stecher VJ, Turnbull BA, Kern PA: Cholesterol-lowering 
 effect of hydroxychloroquine in patients with rheumatic disease: reversal of 





94) Petri M, Perez-Gunthann S, Spence D et al: Risk factors for coronary artery disease in 
patients with SLE. Am J Med 1992; 93: 513-9. 
 
95)  Tam LS, Gladman DD, Hallett DC et al: Effect of anti-malarial agents in the fasting 
lipid profile in SLE. J Rheumatol 2000, 28: 2142-5. 
 
96)  Gladman DD, Urowitz MD:Morbidity in SLE  J Rheumatol 1987;14(suppl 13): 223-6. 
 
97)  Manzi S, Meilahn EN, Rairie JE et al: Age specific incidence rates of myocardial 
infarction and angina in women with SLE: comparison with the Framingham Study. 
Am J Epidemiol 1997; 145: 408-15. 
 
98)  Petri M, Spence D, Bone LR et al: Coronary artery disease risk factors in the Johns 
Hopkins Lupus Cohort: prevalence, recognition by patients and preventative 
Practices. Medicine 1992;  71: 291-302. 
 
99)  Bruce IN, Gladman DD, Urowitz MB: Detection and modification of risk factors for 
coronary artery disease in patients with SLE – a quality improvement study. Clin Exp 
Rheumatol 1998; 16: 435-40. 
 
